

A SHERLOCK toolbox for eco-epidemiological surveillance of African trypanosomes in domestic pigs from Western Africa

Reviewed Preprint

v2 • August 14, 2025

Revised by authors

Reviewed Preprint

v1 • June 17, 2025

Roger-Junior Eloiflin, Elena Pérez-Antón, Aïssata Camara, Annick Dujeancourt- Henry, Salimatou Boiro, Martial N'Djetchi, Mélika Taoré, Mathurin Koffi, Dramane Kaba, Yann Le Pennec, Bakary Doukouré, Abdoulaye Dansy Camara, Moïse Kagbadouno, Pascal Campagne, Mamadou Camara, Vincent Jamonneau, Sophie Thevenon, Jean-Mathieu Bart, Lucy Glover , Brice Rotureau 

INTERTRYP, Université de Montpellier, Montpellier, France • Trypanosome Molecular Biology Unit, Institut Pasteur, Université de Paris, Paris, France • Parasitology Unit, Institut Pasteur of Guinea, Conakry, Guinea • Unité de Formation et de Recherche Environnement, Université Jean Lorougnon Guédé, Daloa, Côte d'Ivoire • Unité de Recherche Trypanosomoses, Institut Pierre Richet, Bouaké, Côte d'Ivoire • Virology Unit, Institut Pasteur of Guinea, Conakry, Guinea • Programme National de Lutte contre la Trypanosomiase Humaine Africaine, Ministère de la Santé, Conakry, Guinea • Bioinformatics and biostatistics hub, Institut Pasteur, Paris, France • Cirad, UMR INTERTRYP, Montpellier, France • Trypanosome Transmission Group, Trypanosome Cell Biology Unit, Institut Pasteur, Université Paris Cité, Paris, France

 https://en.wikipedia.org/wiki/Open_access

 Copyright information

eLife Assessment

This **important** study reports an advancement in the diagnosis of Animal African Trypanosomosis (AAT), which adapts a CRISPR-based diagnostic tool (SHERLOCK4AAT) to detect different trypanosome species responsible for AAT. The evidence supporting the conclusions is **convincing** and in line with the current state-of-the-art diagnostics. This study will be of interest to the fields of Epidemiology, Public Health, and Veterinary Medicine.

<https://doi.org/10.7554/eLife.106823.2.sa4>

Abstract

Animal African trypanosomosis (AAT), caused by protist parasites of the genus *Trypanosoma*, puts upward of a million head of livestock at risk across 37 countries in Africa. The economic impact of AAT and the presence of human-infectious trypanosomes in animals place a clear importance on improving diagnostics for animal trypanosomes to map the distribution of the veterinary parasites and identify reservoirs of human-infectious trypanosomes. We have adapted the CRISPR-based detection toolkit SHERLOCK (Specific High-sensitivity Enzymatic Reporter unLOCKing) for trypanosomatid parasites responsible for AAT (SHERLOCK4AAT) including Pan- trypanosomatid, *Trypanozoon*, *T. vivax*, *T. congolense*, *T. theileri*, *T. simiae* and *T. suis* assays. To test the applicability of this technique in the field, we analysed dried blood spots collected from 200 farm and 224 free-ranging pigs in endemic and historical human

African trypanosomiasis foci in Guinea and Côte d'Ivoire, respectively. The results revealed that SHERLOCK4AAT can detect and discriminate between trypanosome species involved in multiple infections with a high sensitivity. 62.7 % [58.1, 67.3] of pigs were found infected with at least one trypanosome species. *T. brucei gambiense*, a human-infectious trypanosome, was found in one animal at both sites, highlighting the risk that these animals may act as persistent reservoirs. These data suggest that, due to their proximity to humans and their attractiveness to tsetse flies, pigs could act as sentinels to monitor *T. b. gambiense* circulation using the SHERLOCK4AAT toolbox.

Introduction

Through a combination of vector control, reactive screening, passive diagnosis, new therapeutic drugs and the support of national control programmes, donors and stakeholders, interrupting the transmission of gambiense human African trypanosomiasis (HAT) at pan-African level is in reach (Barrett et al., 2024 [↗](#)). Reported annual cases have been maintained below 1,000 since 2018, making the elimination (zero transmission) of gambiense HAT (gHAT) by 2030, one of the major objectives of the World Health Organisation (WHO), achievable (Franco et al., 2024 [↗](#)). Nevertheless, animal African trypanosomiasis (AAT), also known as *nagana*, remains a significant burden to sustainable agricultural development, and represents a threat to livestock and small holder economies (Boulangé et al., 2022 [↗](#)), with a total estimated loss of 4.75 billion USD per year in terms of agricultural gross domestic product in tsetse- infested lands (Budd, 2001 [↗](#)). Unlike HAT, that is caused by either *Trypanosoma brucei* (*T. b.*) *gambiense* in West Africa, or *T. b. rhodesiense* in East Africa, AAT encompasses a wider range of trypanosomatid parasites. In sub-Saharan Africa, animal infecting trypanosomes including *T. vivax*, *T. congolense*, *T. brucei*, *T. theileri*, *T. simiae* and *T. suis* are transmitted by blood-sucking flies, such as Glossinidae and Tabanidae, to a wide range of wild and domestic mammals. Socio-environmental factors such as land cover, humidity, temperature and livestock migration impact trypanosome transmission (Karshima et al., 2016 [↗](#)). This is particularly evident in rural areas of sub-Saharan Africa, where high incidences of *T. brucei*, *T. congolense* and *T. vivax* are observed, due to conditions favourable to the proliferation of flies (Okello et al., 2022b [↗](#)).

Symptoms of AAT are host and pathogen-dependent, with an infection potentially leading to spontaneous abortions, reduction in milk and meat production, delays in sexual maturity, low calving rates, loss of draught power, and ultimately to high mortality, all of which compound poverty in many Sub-Saharan countries (Kristjanson et al., 1999 [↗](#)). Indirect control strategies including the combination of vector control, breeding of trypanotolerant animals, and avoiding grazing in infested areas have proved to be efficient in reducing the number of infections (Meyer et al., 2016 [↗](#)). Chemotherapy and chemoprophylaxis are the main means for controlling AAT, although inadequate usage, presence of fake drugs and emergent drug resistance are hampering trypanocide efficacy (Giordani et al., 2016 [↗](#); Richards et al., 2021 [↗](#)). Reliable and adapted diagnostic tests are crucial for parasite detection to better target infected animals for treatment, as well as for parasite identification to understand the distribution of trypanosomes in endemic areas. Microscopic, serological and molecular methods are generally used to diagnose AAT. Microscopy based methods are the most commonly used diagnostic methods, but lack sensitivity with a limit of detection (LoD) ranging from 10^4 to 10^5 parasites/mL when using fresh blood, to 250 to 5,000 parasites/mL for methods combining centrifugation (Desquesnes et al., 2022a [↗](#)). Serological methods, such as the card agglutination test (CATT) and ELISA, can be used to identify anti-*Trypanosoma* antibodies, but their reliability is often compromised by the poor antigen characterization in animal infecting trypanosomes or by the detection of antibodies from previous infections. In contrast, molecular diagnostic techniques, including PCR and Loop-mediated isothermal amplification (LAMP), offer increased sensitivity (73-100 %) and LoD (1-1000 parasites/mL) by targeting specific regions of the parasites DNA. For the main AAT-related *Trypanosoma* species, pan- species primers (targeting ITS1 for instance) and genus/species/type-

specific primers are available and currently used to detect the DNA of parasites from the subgenus *Nannomonas* (*T. congolense*), *Duttonella* (*T. vivax*) and *Trypanozoon* (*T.b.brucei*, *T. evansi* and *T. equiperdum*) (Álvarez-Rodríguez et al., 2022 [↗](#); Desquesnes et al., 2022a [↗](#)).

AAT-related trypanosome species circulate co-endemically with *T. b. gambiense* in West and Central Africa, where domestic animals such as pigs, dogs, cattle, sheep and goats are suspected reservoirs (Magang et al., 2023 [↗](#); Traoré et al., 2021). In these regions, Suids (warthogs, domestic and bush pigs) and bovids (bushbucks and buffalos) are the preferred hosts for most tsetse fly species (Serem et al., 2024 [↗](#)). In a historical HAT focus in Côte d'Ivoire, free-range pigs sharing the same environment as humans were identified as reservoirs for *T. b. gambiense* (Traoré et al., 2021). The diagnostic techniques employed in this study, involving single round (Radwanska et al., 2002 [↗](#)) or nested PCR (Morrison et al., 2008 [↗](#)), however tended to overestimate the prevalence of the human infective parasites in pigs (Traoré et al., 2021). Therefore, an active and accurate surveillance of the infection status of domestic animals using a more reliable diagnostic tool will be key to reach and sustain gHAT elimination (Simo and Rayaisse, 2015 [↗](#); Vourchakbé et al., 2020 [↗](#)). In addition, a comprehensive map of the animal infective trypanosomes circulating in tsetse-infested areas would enable an improved control strategy and prevent or limit further economic losses.

In this context, developing new diagnostic tools that are species-specific and highly sensitive is essential to accurately diagnose infected individuals and define the circulation of trypanosomes in domestic animals. For this purpose, we have adapted the Specific High-sensitivity Enzymatic Reporter unLOCKing (SHERLOCK) detection that offers unprecedented levels of diagnostic specificity and sensitivity (Gootenberg et al., 2017 [↗](#)), and has been adapted for the detection of HAT (Sima et al., 2022 [↗](#)). SHERLOCK combines an isothermal amplification by recombinase polymerase (RPA) with Cas13a detection of the target RNA (Gootenberg et al., 2017 [↗](#); Kellner et al., 2019 [↗](#); Piepenburg et al., 2006 [↗](#)). The RPA step, in combination with a reverse transcriptase, allows the use of total nucleic acid (TNA) as an input, increasing the flexibility of the assay. Here, we have developed a broad panel of SHERLOCK assays for the detection of the six most prevalent AAT-related species. We have applied the SHERLOCK4AAT panel to two populations of domestic pigs from two eco-epidemiological regions of West Africa to determine their importance as reservoirs of both animal and human-infective trypanosomes. A total of 424 blood samples were collected (1) from free-ranging pigs in the last hypo-endemic foci of gHAT in Côte d'Ivoire, and (2) from farm pigs bred in the historical gHAT focus of forested Guinea where unconfirmed seropositive cases of gHAT are still sporadically detected (Courtin et al., 2019 [↗](#)). These samples were screened using the complete SHERLOCK4AAT panel to provide an in-depth profile of the trypanosome species circulating among these domestic animals.

Materials and Methods

Ethics statement

The only reliable method available to maintain and amplify field-isolated animal trypanosomes is to experimentally infect laboratory animals, here mice. For this study, experimental infections were carried out at UMR INTERTRYP and were approved by the regional ethics committee for animal experimentation as part of the project APAFIS #34149-2020091118136527v5 and authorized by the French Ministry for Higher Education and Research. In Guinea, ethical approval was obtained from the *Comité National d'Ethique pour la Recherche en Santé* (CNERS) under agreement number 102/CNERS/19. In Côte d'Ivoire, sample collection was conducted within the framework of epidemiological surveillance activities supervised by the HAT National Elimination Program (HAT-NEP). No ethical statement is required by local authorities for domestic animal sampling. Any veterinarian may carry out blood sampling on domestic animals, with the authorization of the owner, as it is performed during prophylaxis or diagnostic campaign. Breeders gave their consent

for animal sampling after being informed of the objectives of the study. For pig care, venous sampling was performed by a veterinary of the Laboratoire National d'Appui au Développement Rural (Ministry of Agriculture).

Mice infection and parasite purification

24 hours prior to infection with trypanosome parasites, 8-week-old female BALB/c mice (Charles River Laboratory) were immunosuppressed by intraperitoneal injection of 0.1 mL Endoxan 500 mg (Baxter). *T. congolense* Savannah subgroup IL1180 strain (Tanzania, Serengeti 1971, STIB212), *T. vivax* Magnan strain (Burkina Faso, Magnan 2011) and *T. theileri* (Nederland, Utrecht 2003, UNUT) parasites (INTERTRYP unit's cryobank) were inoculated by intraperitoneal injection of 0.15 mL of the cryopreserved blood containing parasites. Two mice were infected per strain and parasitaemia was monitored daily by tail blood sampling. Parasite yields were estimated by counting in a fast read 102 counting cells (Kova). Whole blood was collected by cardiac puncture under deep isoflurane anaesthesia when parasitaemia reached 1×10^8 cells per mL. Infected blood was passed over a diethylaminoethyl (DEAE)-cellulose column and the column washed using phosphate buffer saline (PBS) supplemented with 1 % glucose (PBSG). Parasites were collected in PBSG and concentrated by centrifugation (2000 rpm, 10 min, RT).

Cell culture

T. b. brucei Lister 427 bloodstream form and *T. b. gambiense* ELIANE cells were cultured in HMI-11 medium (ThermoFisher scientific) supplemented with 10 % fetal bovine serum (Sigma) at 37°C with 5 % CO₂. Human embryonic kidney (HEK) 293T cells were cultured in complemented dMEM (Merck) at 37°C with 5 % CO₂.

Epidemiological surveys

Pig blood samples were collected from the external jugular vein in heparinized tubes during two independent surveys in Côte d'Ivoire and Guinea. In Côte d'Ivoire, 224 free- ranging pigs were sampled in May, June and July 2021 in the Bonon and Sinfra hypoendemic HAT foci, the Bouaflé and Vavoua historical HAT foci and the Brobo HAT-free area [Kaba, 2023 #8655]. In Guinea, 200 farm pigs were sampled in March 2023 in the N'zérékoré prefecture, an ancient gHAT focus. Four drops of blood were dried on 4th grade Whatman filter paper (Cytivia Life Sciences) and conserved in sealed plastic bags with silica gel at ambient temperature for several months until total nucleic acid (TNA) extraction.

Nucleic acid extraction

RNA was extracted from bloodstream form parasites (*T. b. brucei* Lister 427, *T. b. gambiense* ELIANE, *T. congolense* Savannah subgroup IL1180, *T. vivax* Magnan and *T. theileri*), HEK 293T cells and whole blood from French cattle, pig, sheep and goat (Bergerie de la Combe aux Loups). Bloodstream form parasites from infected mice, as well as cultured HEK 293T cells, were harvested in TRIzol (Life Technologies) and Chloroform:Isoamyl alcohol (24:1, Sigma-Aldrich) was added, followed by centrifugation at 13,000 rpm at 4°C for 15 min. The upper aqueous phase was transferred to a fresh tube containing 0.5 mL of 75 % ethanol. After incubation for 10 min at room temperature, RNA was extracted using a NucleoSpin RNA column (Macherey Nagel) or a RNeasy kit (Qiagen) according to the manufacturer's instructions. 500 µL of blood sampled from French cattle, pig, sheep and goats was treated with 500 µL lysis buffer supplemented by 50 µL Proteinase K and incubated for 30 min at 56°C. The resulting mixture was transferred into a QIAshredder column (Qiagen) and centrifuged at 13,000 rpm for 2 min. The flow-through was then used for RNA extraction using a RNeasy Mini kit (Qiagen) according to the manufacturer recommendations. After extraction, qualities and quantities of RNA were evaluated using the NanoDrop™ One (Ozyme).

For extraction of TNA from dry blood spots (DBS), three 6 mm-punches from one spot of each animal DBS were resuspended in 300 µL of lysis buffer supplemented by 30 µL of Proteinase K and incubated for 30 min at 56°C. The punches and liquid were transferred into a QIAshredder column (Qiagen) and centrifuged at 13,000 rpm for 2 min. TNA was extracted from the flow-through using the Maxwell RSC Buccal Swab Kit (AS1640) with the Maxwell RSC Instrument (AS4500) according to the manufacturer's instructions. For each sample, all SHERLOCK assays were performed from a single TNA extraction.

Target selection, RPA primers and crRNAs design

Alignments of the *18S rRNA*, *IFX* and *GAPDH* genes were performed on sequences from different species (Supplementary Table 1) using Clustal Omega (Sievers and Higgins, 2018). The distance matrix representing the percentage identity between each sequence was represented using GraphPad Prism software (V.10).

BLAST analysis (McGinnis and Madden, 2004) of the *18S rRNA* and *GAPDH* genes selected target sequences was performed in the NCBI standard database of using the following selection of organisms: Microsporidia (taxid:6029), Ciliophora (taxid:5878), Haemosporida (taxid:5819), Diplomonadida (taxid:5738), Symbiontida (taxid:797087), Diplonemea (taxid:191814), Euglenida (taxid:3035), Kinetoplastea (taxid:5653), Metakinetoplastina (taxid:2704647), Trypanosomatida (taxid:2704949), Trypanosomatidae (taxid:5654) and Euglenozoa (taxid:33682). The program selection was optimized for somewhat similar sequences (blastn) and in algorithm parameters, the maximum number of aligned sequences to display was set as 5000.

The presence of single nucleotide polymorphism (SNPs) in the target regions was assessed by aligning sequence variants of the parasite species using Clustal Omega (Sievers and Higgins, 2018). Sequence variants used are listed in Supplementary Table 1. SNPs identified in the TriTrypDB (<https://tritrypdb.org>) database were also taken into account in the design: NGS_SNP.Tb927_03: v5.1.921431, v5.1.921465, v5.1.921571, v5.1.921612, v5.1.921937, v5.1.922234, v5.1.922298, v5.1.922511, v5.1.922637, v5.1.922803, v5.1.923180, v5.1.959274; NGS_SNP.Tb927_07: v5.1.1951525, v5.1.1952283, v5.1.1951291; NGS_SNP.Tb927_02: v5.1.371291, v5.1.371584 and v5.1.370058.

Primers for Recombinase Polymerase Amplification (RPA) of targeted regions were designed in Primer-BLAST (Ye et al., 2012) using the customised parameters described by (Kellner et al., 2019). Oligonucleotides prone to generate self-dimers or cross primer dimers detected by Multiple Primer Analyzer (ThermoFisher) were discarded. Primers selected for each SHERLOCK assays are listed and highlighted in Supplementary Table 2. The T7 promoter sequence (5' GAAATTAATACGACTCACTATAGGG) was added at each 5' end of the selected forward primers to enable the *in vitro* transcription necessary for Cas13a detection (Kellner et al., 2019).

Production of crRNAs and positive controls

crRNA production was carried out as previously described (Kellner et al., 2019; Sima et al., 2022). Briefly, each crRNA DNA template, containing the spacer (specific targeted region) followed by the direct repeat (5' GATTAGACTACCCAAAAACGAAGGGGACTAAAC) and the T7 promoter sequence, were *in vitro* transcribed using the HiScribe™ T7 Quick High Yield RNA Synthesis Kit (NEB) and purified using magnetic beads (Agencourt RNAClean XP). DNA template sequences used for the synthesis of each crRNA are detailed in Supplementary Table 2.

For the production of the synthetic positive controls, *in vitro* transcription of the targets was performed as previously described (Sima et al., 2022) using RNA from the target species for each specific assay. The amount of template used to produce the positive control for each assay were as follows: 200 ng of RNA from *T. b. brucei* Lister 427 for 18S pan-trypanosomatid and 18S pan-*Trypanozoon* assays, 120 ng of RNA from *T. b. gambiense* ELIANE strain for TgSGP assay, 120 ng of

RNA from *T. vivax* Magnan strain for IFX assay, 230 ng of RNA from *T. congolense* Savannah subgroup IL1180 strain for 18S *T. congolense*-specific assay and 5 ng of RNA from *T. theileri* for 18S *T. theileri*-specific assay. Due to a lack of *T. simiae* and *T. suis* genetic material, the positive controls were synthesized at Eurogentec using the *in-silico* predicted sequence of the target region. Primers and target regions used to produce positive controls are listed in the Supplementary Table 3.

SHERLOCK assays

SHERLOCK assays were performed as previously described (Kellner et al., 2019; Sima et al., 2022). RPA was performed using the TwistAmp Basic kit (TwistDx) following manufacturer's instructions with slight modifications. To enable reverse transcription of the RPA (RT-RPA), 2.2 U of transcript reverse transcriptase (Roche) were added to the reaction. Specific RPA primer pairs were used for each target amplification at a concentration of 480 nM per primer, and the amplification reaction was carried out in a heating block at 42°C for 45 minutes (Sima et al., 2022). *Leptotrichia wadeii* Cas13a (*LwCas13a*) enzyme was produced as previously described (Kellner et al., 2019; Sima et al., 2022). Briefly, pC013-Twinstrep-SUMO- huLwCas13a plasmid (Addgene plasmid #90097) was inserted into *Escherichia coli* RosettaTM 2(DE3) pLysS competent cells for *LwCas13a* expression and purification (Gootenberg et al. 2017). Purified *LwCas13a* was conserved in Storage buffer (SB: Tris-HCl 1M, NaCl 5M, DTT 1M and glycerol) (Kellner et al., 2019) in single-use aliquots at -80°C to avoid freeze-thaw cycles.

The Cas13a-crRNA mediated target detection reaction was performed simultaneously with the *in vitro* transcription of the target amplified by RT-RPA. *In vitro* transcription of the amplified target was performed using T7 RNA polymerase (Biosearch technology). Each Cas13a detection reaction was run in triplicate on a TECAN plate reader (INFINITE F200 PRO M PLEX) and fluorescence readouts were collected every 10 minutes for 3 hours. All reactions were carried out with the inclusion of a negative control template (NCT) adding nuclease-free water as input, and a positive control template (PCT), here the *in vitro* produced positive control for each specific SHERLOCK. For screening samples from epidemiological surveys, the same protocol as described above was used, except a TECAN plate reader (INFINITE F200 PRO Option Infinite F Nano +) was used and the assay was performed without replicates. Optimizations were carried out either at Institut Pasteur in Paris (France) or at INTERTRYP unit in Montpellier (France), while analysis of samples from epidemiological surveys was carried out at Institut Pasteur of Guinea.

Data representation and statistical analyses

Fold-change over background fluorescence was used to represent fluorescence readouts for all SHERLOCK assays. Background fluorescence is given by the NCT evaluation, where water is used as input material for the RPA reaction. For each test, sample fluorescence obtained after 3 hours of reading was divided by NCT fluorescence at the same time.

$$FC = \frac{F_{sample\ t=3h}}{F_{nct\ mean\ t=3h}}$$

Where *FC* represents Fold-Change over background fluorescence, *Fsample t=3h* represents sample fluorescence obtained after 3 hours and *Fnct mean t=3h* represents NCT fluorescence after 3 hours of reactions.

Analytical characteristics including threshold, sensitivity and specificity of each SHERLOCK assay were evaluated using Receiver Operating Characteristic (ROC) curves calculation comparing NCT versus PCT at controlled dilutions of parasites or hosts genetic materials. Results obtained from SHERLOCK specific assays on targeted parasites were gathered in a positive sample column, while results obtained from NCT, hosts and non-targeted parasites analysed with the assay, were placed in a negative sample column for ROC curve calculation and threshold evaluation. ROC curves were calculated using the Wilson/Brown method with a 95 % confidence interval and threshold values were selected based on the Youden's index (sensitivity + specificity – 1), that defines an optimal

threshold as the one that maximizes the index of classification accuracy (Brown et al., 2001 [↗](#); Schisterman et al., 2005 [↗](#)). The threshold of positivity for each SHERLOCK assay was selected from ROC analyses as the value corresponding to the maximum specificity (100 %). The limit of detection (LoD) of each SHERLOCK reaction was assessed using specific tests on serial dilutions of target parasite RNA. Dilutions ranged from 5.10^3 pg/ μ L (equivalent to 10^7 parasites/mL) to 5.10^{-5} pg/ μ L (equivalent to 0.1 parasites/mL). All plots and statistical analyses were performed with GraphPad Prism software (V.10). The Venn diagrams were made based on the Venny model by Oliveros J.C. (BioinfoGP, CNB-CSIC).

Maps were generated with the QGIS software version 3.42.0 with backgrounds retrieved from data.gouv.fr (OSM2IGEO - Ivory Coast - SHP - EPSG:4326 for Côte d'Ivoire, and OSM2IGEO - Guinea - SHP - EPSG:4326 for Guinea).

In the absence of reliable infection status in the field data from pigs, the posterior distributions of performance estimates, such as sensitivity (Se), were jointly estimated with a Bayesian latent class model (Joseph et al., 1995 [↗](#)). The model takes boolean outcomes (either positive or negative) of several tests as input. This Monte Carlo method operates based on a Gibbs sampling process. The model iteratively updates both the test performance parameters (sensitivity, specificity, and frequency of positive individuals in sample collection) and the latent infection status. Flat prior was used. After visually controlling that stationarity of the chain was quickly reached, we discarded the first 150 burn-in iterations and calculated posterior densities based on > 10,000 iterations. 95 % confidence intervals were calculated for each proportion to quantify the uncertainty of the estimates, providing a scientific range within which the population proportions are likely to be accurate (Brown et al., 2001 [↗](#)).

Results

Selection of targets for broad and species-specific SHERLOCK assays targeting AAT species (SHERLOCK4AAT)

Target gene selection was based on two requirements: to develop (a) a broad SHERLOCK assay for the detection of all trypanosomatid parasites and (b) for species discrimination. To adapt SHERLOCK for the detection of AAT-related species, we followed the criteria as described in (Sima et al., 2022 [↗](#)). Briefly, candidate genes must (1) be expressed in the bloodstream form of the parasites, (2) be conserved between strains, (3) have few or no single nucleotide polymorphisms (SNPs), or (4) show sequence divergence that would allow for species discrimination. All RPA primers and crRNAs designed for each SHERLOCK assays are listed in Supplementary Table 2.

Pan-trypanosomatid assay

SHERLOCK has the capacity to discriminate between two sequences differing by a single nucleotide (Gootenberg et al., 2017 [↗](#)). This study therefore focused on regions of the *18S rRNA* gene that show limited sequence homology between species. In addition to being a multicopy gene, the *18S rRNA* gene shares over 70 % identity between Kinetoplastea members (Supplementary Figure 1). Using BLAST analysis, the region between 1535-1672 bp (XR_002989632.1) was found to be conserved between all trypanosomatid species and was selected as the pan-trypanosomatid SHERLOCK target. RPA primers were designed to amplify this 138 bp region using Primer-Blast (Ye et al., 2012 [↗](#)) (Supplementary Figure 2A and Supplementary Table 2). The level of identity of the target region was assessed between the different sequences described in the Trypanosomatidae family, as well as in the order, subclass and class that contain this family (Supplementary Figure 3). Examination of the Euglenozoa phylum, excluding the Kinetoplastea class, showed

98.4 % identity within the Trypanosomatidae family and 97.3 % identity within the Kinetoplastea class (Supplementary Figure 3). This was reduced to 82.9 % for the Phylum Euglenozoa, excluding the Kinetoplastea sequences (Supplementary Figure 3). Three distinct crRNAs were designed to this region, which can be used individually or multiplexed to increase the sensitivity (Supplementary Figure 4A and Supplementary Table 2). The sequences described in each group were 100 % conserved to the crRNA. RPA primers and crRNA targets of the pan-trypanosomatid SHERLOCK assay target regions (Kinetoplastea) were then compared to the homologous sequences from other classes within the Phylum Euglenozoa (Euglenida, Diplonemea, Symbiontida and Kinetoplastea) (Supplementary Figure 2A and 3). In addition, sequences from related protozoan parasite classes (Diplomonadida, Haemosporida and Ciliophora) and from the genetically close but phylogenetically distinct group Microsporidia were also included in the analysis (Supplementary Figure 2A).

Pan-Trypanozoon assay

A pan-Trypanozoon SHERLOCK assay was designed for increased selectivity to especially detect *T. brucei* s.l. (*sensu lato*). The regions within the 18S rRNA that were highly conserved among the species of the *Trypanozoon* subgenus, while showing significant divergence from other trypanosome species not belonging to the *Trypanozoon* subgenus, were analysed (Supplementary Figure 2B). A region ranging from 1318 to 1433 bp (XR_002989632.1) (Figure 1A and Supplementary Table 2) was selected as it showed high conservation among the *Trypanozoon* subgenus (99.12 - 100 % percentage of identity, query coverage >90 %), except for three *T. evansi* sequences (91.96 - 96.49 %, OL869590.1, KT844944.1, MF142286.1). The crRNA target region selected was also conserved in the subgenus *Trypanozoon* and divergent in other parasites. Specific alignments with trypanosome species that could share the same hosts (*T. congolense*, *T. vivax*, *Leishmania* spp., etc) were performed to assess target amplicon specificity (Supplementary Figure 2B). The pan-Trypanozoon SHERLOCK assay can discriminate between the species belonging to the *Trypanozoon* subgenus (*T. b. spp.*, *T. evansi* types A and B, and *T. equiperdum*) from other non-Trypanozoon trypanosomes or other co-endemic parasites.

Species-specific assays

For species discrimination within a single sample, several SHERLOCK assays were developed to detect the most prevalent species causing AAT. These include *T. congolense*, *T. vivax*, *T. theileri*, *T. simiae* and *T. suis*. *T. congolense*: Regions conserved in the 18S rRNA gene for all described *T. congolense* sequences, including the Savannah, Forest, Kilifi and Dzanga-Sangha groups, were analysed. The target region selected from position 116 to 246 bp of the 18S rRNA gene (AJ009146.1) shows 100 % identity between the described *T. congolense* sequences. BLAST analysis of the *T. congolense* 18S rRNA gene sequences, excluding the target species (*T. congolense*, (taxid: 5692)) was also performed to determine the percentage of identity of closely related species. *T. simiae* (86.72 to 90.62 %), *T. sapaensis* (88.28 %), *T. godfreyi* (88.28 %), and *T. otospermophili* (87.02 %) had the highest percentage identity observed (Supplementary Figure 5). Species with common hosts and of veterinary relevance such as the two analysed *T. vivax* strains showed 82.81% and 87.5% identity. In addition, none of these sequences were fully conserved for the selected crRNA (Supplementary Figure 5), ensuring the specificity of the test and the absence of cross- detection with other species.

T. vivax: The invariant flagellum antigen (IFX) gene has no apparent homologue in any other *Trypanosoma* species or other related parasites, and was therefore selected (Autheman et al., 2021; Romero-Ramirez et al., 2022). BLAST analysis, using *T. vivax* Y486 (HE573024.1) as a reference genome, resulted in no matches (Figure 1A and Supplementary Table 2).

T. theileri: A conserved region between the three *T. theileri* lineages (TthI, TthII and TthIII) (Brotánková et al., 2022) was selected. The target region, ranging from 1014 to 1158 bp of the 18S rRNA gene (AJ009163.1), has 100 % identity between the described sequences of the *T. theileri* lineages, and the most closely related sequences were from *T. cruzi*, *T. rangeli* and *T. dionisii*, with a




Figure 1.

Pan and species-specific SHERLOCK assays for human and animal African trypanosome infections.

(A) Schematic of the target regions used in the SHERLOCK4AAT toolbox. *T. congolense*, *T. theileri* (multiplex), *T. simiae*, Pan-*Trypanozoon* and Pan-trypanosomatid SHERLOCK assays were designed using the 18S rRNA gene as a target; *T. vivax* SHERLOCK assay using the IFX gene and *T. suis* test using the gGAPDH gene. Gene specific accession number in brackets below the assay name. Details of the regions amplified are provided for each SHERLOCK assay (amplicon). RPA primers are represented by black arrows, the extension in the forward primer represents the T7 polymerase promoter sequence. The regions targeted by the crRNAs (CRISPR guides) are also indicated in the diagram. The schematic representation is to scale. (B) Evaluation of the specificity of single pan- trypanosomatid and pan-*Trypanozoon* SHERLOCK tests RNA from *T. b. brucei* (*Tbb*), *T. b. gambiense* (*Tbg*), *T. b. rhodesiense* (*Tbr*), *T. evansi* A (*TevA*) and B (*TevB*), *T. equiperdum* (*Teq*), *T. congolense* (*Tcg*), *T. vivax* (*Tvx*), *T. theileri* (*Tth*), *Leishmania major* (*Lm*), *Plasmodium falciparum* (*Pfl*) and HEK cells. The boxplot means are represented by single lines, and error bars correspond to minimum and maximum values. N=3 for the RPA amplifications and three Cas-13a detections for each RPA amplification, totalling 9 replicates for each assay. *T. theileri* was used in fewer replicates as an input due to the limited genetic material available. (C) Evaluation of the specificity of *T. congolense*, *T. vivax*, *T. theileri*, *T. simiae* and *T. suis*-specific SHERLOCK tests on RNA from *Tbb*, *Tbg*, *Tcg*, *Tvx*, *Tth*. Synthetic controls for *T. simiae* (*Tsm*) and *T. suis* (*Tsu*) were used to evaluate the species-specificity of the assays. N=1 RPA amplification and three Cas-13a detections totalling 3 replicates for each assay. Error bars represent standard deviations from the mean of the replicates. All inputs were used at a concentration of 5 ng/μL.

97.89 % identity (query coverage =65 %). The segment 1052-1081 bp corresponding to the crRNA sequence, is highly conserved between *T. theileri* variants (**Figure 1A** and Supplementary Table 2), however it contains a SNP (1060 C/T) in a number of the sequences analysed. Hence, one RPA primer pair and two multiplexed crRNAs were designed to target both version of the SNP for the *T. theileri* SHERLOCK assay (Supplementary Figure 4E).

T. simiae: The region from 1246-1346 bp of the 18S rRNA gene (AJ404608.1) was selected as the targeted region for RPA amplification of the *T. simiae*-specific SHERLOCK assay. The segment 1273-1299 bp that corresponds to the crRNA sequence, has 100 % identity between the described sequences of *T. simiae* (**Figure 1A** and Supplementary Table 2).

T. suis: The multicopy *GAPDH* gene was used, as it can be phylogenetically separated into *T. suis* and *T. suis*-like strains from other African trypanosomes (Rodrigues et al., 2020). The region from 389 to 528 bp of the *GAPDH* gene (MK962702.1) has been selected as the targeted region for RPA amplification of the *T. suis*-specific SHERLOCK assay (**Figure 1A** and Supplementary Table 2). This region is 100 % conserved between the *T. suis* species described, and outside this clade, the most closely related sequences were found in *T. congolense*, with a 90 % of identity (query coverage >90 %). The segment 410-437 bp of the *gGAPDH* gene (MK962702.1), that corresponds to the crRNA target region, is highly conserved between *T. suis* species, with 100 % identity, and the BLAST analysis showed that this target fragment can only align to *T. suis* sequences but not to that of other Kinetoplastea species (taxid:5653).

SHERLOCK can discriminate between closely related AAT-causing trypanosomatid species

All RPA primers and crRNAs for each targeted species were screened to select the optimal combinations, with the highest specificity and selectivity. For the pan- trypanosomatid assay, RPA primer pair A was used to screen three crRNAs (A:crRNA1, A:crRNA2 and A:crRNA3; Supplementary Figure 4A). From this, crRNA 3 was first selected for the simple pan-trypanosomatid assay. For the pan-*Trypanozoon* assay, three RPA primer pairs (A, B and C) were screened with two crRNA candidates each (A:crRNA1, A:crRNA2, B:crRNA1, B:crRNA2, C:crRNA1, C:crRNA2, Supplementary Figure 4B). The A:crRNA1 combination was selected for the pan-*Trypanozoon* assay, being the one that obtained a higher fold change for the positive control and a lower fold change for the negative control. For the IFX *T. vivax* species- specific SHERLOCK assay, two RPA primer pairs were assessed (A and B) in combination with six crRNA candidates (A:crRNA1, A:crRNA2, A:crRNA3, B:crRNA4, B:crRNA5, B:crRNA6). RPA primer pair B and crRNA 6 showed the lowest variability between replicates and without any cross-reaction with other trypanosome species (Supplementary Figure 4C). For the *T. congolense*-specific assay, one pair of RPA primer (A) was combined with ten crRNA candidates (A:crRNA1, A:crRNA2, A:crRNA3, A:crRNA4, A:crRNA5, A:crRNA6, A:crRNA7, A:crRNA8, A:crRNA9, A:crRNA10). The crRNA1 that exhibited the lowest inter-replicate deviation and no cross-reactivity when exposed to the genetic material of non-target trypanosomatid parasites was selected (Supplementary Figure 4D). For the *T. theileri*-specific SHERLOCK assay, the combination of the RPA primer pair A with the two designed crRNAs (1 and 2) was used to cover the specific detection of all the *T. theileri* described sequences (Supplementary Figure 4E). For *T. simiae* and *T. suis*, single combinations of RPA primer and crRNA were tested. The specificity of each of these combinations was also verified by comparing the specific recognition of each RNA target to RNA from human embryonic kidney cell (HEK) (for pan-trypanosomatid and pan- *Trypanozoon* tests) or RNA from *T. brucei* (for *T. vivax*, *T. congolense* and *T. theileri* tests) (Supplementary Figure 4). In total, one RPA primer-crRNA combination was selected for each assay, based on the highest fold change over background fluorescence value, the highest specificity, and the minimum standard deviation (**Figure 1A**).

The specificity of the RPA primer-crRNA combinations selected for each assay was then cross-assessed against closely related parasites (**Figure 1B-C**). The single pan-trypanosomatid assay detected RNA from all trypanosomatid species tested (*T. b. brucei*, *T. b. gambiense*, *T. b. rhodesiense*, *T. evansi* (type A and B), *T. equiperdum*, *T. congolense*, *T. vivax*, *T. theileri*, *T. cruzi* and *Leishmania major*) but not from HEK cells, synthetic controls for *T. simiae* and *T. suis* or co-endemic parasites such as *Plasmodium falciparum* (**Figure 1B**). The pan-*Trypanozoon* assay detected only RNA from members of the *Trypanozoon* subgenus (*T. b. brucei*, *T. b. gambiense*, *T. b. rhodesiense*, *T. evansi* (type A and B) and *T. equiperdum*) but not from HEK cells, synthetic controls for *T. simiae* and *T. suis* or co-endemic parasites such as *T. congolense*, *T. vivax*, *T. theileri* and *Plasmodium falciparum* (**Figure 1B**). The species-specific *T. congolense*, *T. vivax*, *T. theileri*, *T. simiae* and *T. suis* assays only detected their respective targeted parasite RNA or synthetic controls with no cross reactivity with any other RNAs (**Figure 1C**). Additionally, no unspecific cross-reaction was observed with the host-derived genetic material, as assessed by testing RNA from pig blood (SHERLOCK single pan-trypanosomatid and pan-*Trypanozoon* assays in Supplementary Figure 7).

The analytical sensitivity of each assay was quantified using serial dilutions of positive control RNAs from known numbers of parasites. For the single pan-trypanosomatid assay, the LoD was between 10 to 10^3 parasites per mL. The pan-*Trypanozoon* and *T. theileri* assays tested 10 parasites per mL. For the *T. congolense* assay, the LoD was found between 10 and 10^3 parasites per mL, and between 10^4 and 10^5 parasites per mL for the *T. vivax* test (**Figure 2A**). The sensitivity of *T. simiae* and *T. suis* tests were evaluated on synthetic positive controls, as no genetic materials were available, and both showed a LoD between 10 and 100 fM (**Figure 2B**).

Then, to improve the sensitivity of the simple pan-trypanosomatid assay, crRNA1 was tested in combination with crRNA3 for target recognition, as both crRNAs fall within the same RPA amplicon A (**Figure 3A**). Comparative analyses between the two versions were performed and multiplexing was shown to increase the performance of the assay, especially for the lower dilutions evaluated (100, 500 and 10^3 p/mL) by increasing the fold-change readouts of these positive controls by 1, 2.5 and 3-fold-change units, respectively (Supplementary Figure 6). Using results obtained on the blood samples from pigs in Côte d'Ivoire (see next section), we compared the two versions of the pan-trypanosomatid SHERLOCK assays to determine the posterior distribution of sensitivity estimates. We applied a Monte Carlo method (Gibbs sampling) proceeding in an iterative chain using the infection frequency, specificity, and sensitivity of the two tests to update the infection status. We determined the posterior sensitivity distribution of the simple versus multiplex pan-trypanosomatid SHERLOCK assays. Multiplexing crRNAs increased the median sensitivity from 66.1 % to 74.7 %, while keeping specificity above 80 % (**Figure 3B**). Furthermore, a higher concordance was observed between the results obtained on the same samples with the pan-*Trypanozoon* SHERLOCK assay and the multiplexed pan-trypanosomatid SHERLOCK assay (25.7-% of double positives), as compared to the simple version (7.8 % of double positives) (**Figure 3C**). Given its improved detection efficiency, the multiplex version of the 18S rRNA pan-trypanosomatid assay was subsequently used exclusively and referred to as the multiplex pan-trypanosomatid assay.

To determine a positivity threshold value (fold-change cut-off) for each SHERLOCK assay, ROC curve analyses were performed and used to evaluate each following analytical sensitivity and specificity. The positivity threshold values were 6.050 for the pan-trypanosomatid test, 11.70 for the pan-*Trypanozoon* test, 1.923 for the *T. congolense* test, 1.831 for the *T. vivax* test, 1.805 for the *T. theileri* test, 1.546 for the *T. simiae* test, and 2.609 for the *T. suis* test (Supplementary Figure 8). Subsequently, for a given test, any sample with a fold change value above the threshold was considered positive for this test. Unsurprisingly, assays designed against multiple copy genes (18S rRNA and *GAPDH*) showed a greater sensitivity than those targeting single copy genes (*IFX*). Taken together, all the validated tests were able to specifically detect the RNA targets for which they were




Figure 2.

Evaluation of the sensitivity of SHERLOCK assays targeting trypanosome species causing AAT.

(A) Limit of detection (LoD) assays for the single pan-trypanosomatid, pan-Trypanozoon, *T. vivax*, *T. congolense* and *T. theileri* assays were performed using RNAs from bloodstream parasites diluted to obtain equivalent concentrations of parasites per mL, ranging from 10^7 to 0.1 parasites/mL. (B) LoD of *T. simiae* and *T. suis* assays were performed on consecutive dilutions of the synthetic controls, ranging from 10^{10} to 10^1 fM. N=24 for pan-trypanosomatid assay, N=12 for pan-Trypanozoon and *T. theileri* assays, N=6 for *T. simiae* assay and N=3 for *T. congolense*, *T. vivax* and *T. suis* assays. Error bars represent standard deviations from the mean of the replicates; open circle represents each replicate.




Figure 3.

Comparison of the single and multiplex 18S pan-trypanosomatid SHERLOCK assays efficiency.

(A) Schematic of the single (one crRNA) and multiplex (two crRNAs) pan-trypanosomatid SHERLOCK assays designed using the 18S rRNA gene as a target. Gene specific accession number in brackets below the assay name. Details of the amplified gene regions are provided (amplicon). RPA primers are represented by black arrows; the forward primer extension represents the T7 polymerase promoter sequence. The regions targeted by the crRNAs are indicated in the diagram. (B) Posterior sensitivity estimates of the single (green) and multiplex (purple) pan-trypanosomatid SHERLOCK assays on the 224 pig blood samples from Côte d'Ivoire presented in [Figure 4](#). Estimates were obtained with the Monte Carlo method (Gibbs sampling) proceeding in an iterative chain. (C) Results of pan- *Trypanozoon* SHERLOCK assay plotted against results of the single (left panel) and multiplex (right panel) 18S pan-trypanosomatid SHERLOCK assays on pig samples from Côte d'Ivoire. The coloured dashed lines represent the detection thresholds set for each of the tests: single pan-trypanosomatid (green), multiplex pan-trypanosomatid (purple), and pan-*Trypanozoon* (orange). Numbers and proportions (%) of double positive samples are indicated at the top right of each graph and only positive for pan- trypanosomatid in the bottom right part of each graph.

designed, making it possible to distinguish between closely related trypanosomatid parasite species. We then applied this novel SHERLOCK4AAT toolbox was applied to the analysis of field samples in a molecular eco-epidemiological survey.

Application of the SHERLOCK4AAT toolbox to eco-epidemiological surveys in pigs

In transmission foci of western Africa, domestic pigs can host multiple trypanosome species. To investigate this, the SHERLOCK4AAT toolbox was used to survey trypanosomes circulating in domestic pigs from hypo-endemic and historical foci in Côte d'Ivoire and Guinea. In Côte d'Ivoire, blood samples were collected from 224 free- ranging pigs across the rural districts of Bonon, Bouaflé, Sinfra, Vavoua, and Brobo (**Figure 4A** [↗](#)). In the N'zérékoré prefecture of Forested Guinea, 200 farm pigs were sampled, with a focus on organized farming communities (**Figure 5A** [↗](#)). In addition to the SHERLOCK4AAT toolbox assays, all samples were also screened for *T. b. gambiense* using the previously described TgsGP SHERLOCK assay (Sima et al., 2022 [↗](#)).

In total, 74.6 % [68.9, 80.3] (167/224) of the samples tested positive in at least one SHERLOCK assay in Côte d'Ivoire (**Figure 4B** [↗](#)), and 49.5 % [42.6, 56.9] (99/200) in Guinea (**Figure 5B** [↗](#)) representing a high apparent prevalence of trypanosome infections in these two populations of pigs. In parallel, 47.3 % [40.8, 53.8] (106/224) of the pigs from Côte d'Ivoire tested positive using at least one parasitological method (buffy coat examination, mAECT and /or isolation in mice; results detailed in a separate study, manuscript in preparation). No systematic parasitological data was available for Guinean samples. The difference in positivity rates between SHERLOCK detection and parasitological approaches on Ivoirian samples was likely due to the higher sensitivity of SHERLOCK as compared to classical methods. Indeed, we compared three SHERLOCK assays (multiplex pan-trypanosomatid, pan-*Trypanozoon* and *T. congolense*-specific SHERLOCK assays) to the three parasitological tests (buffy coat examination, mAECT and /or isolation in mice) to determine the posterior distribution of sensitivity estimates. A Monte Carlo method (Gibbs sampling) was used by proceeding in an iterative chain using the infection frequency, specificity, and sensitivity of the tests to update the infection status. This analysis suggested that, in terms of sensitivity, the combination of SHERLOCK4AAT assays may compete with combined parasitological methods (i.e., median sensitivity 91.4 % vs 84.3 %) while controlling median specificity above 75 % (Supplementary Figure 9). Importantly, in contrast to parasitological tests, SHERLOCK4AAT allowed for the identification of the trypanosome species involved in more than half of these infections.

Using the multiplex pan-trypanosomatid assay, 41.1 % [34.6, 47.6] of the samples from Côte d'Ivoire (90/219) and 29.5 % [23.2, 35.8] from Guinea (59/200) were positive (**Figure 4C** [↗](#) and **5C** [↗](#)). The pan-*Trypanozoon* assay identified 38.0 % [31.6, 44.4] (85/224) and 39.0 % [32.2, 45.8] (78/200) of samples in each country respectively (**Figure 4C** [↗](#) and **5C** [↗](#)). As there is no specific test for *T. b. brucei*, samples that were positive in the pan-*Trypanozoon* assay but negative in the TgsGP assay were presumed to be *T. b. brucei* infections. Only one sample tested positive in the *T. b. gambiense*-specific assay in each country (**Figure 4B** [↗](#) and **5B** [↗](#)). The TgsGP-positive sample from the district of Bonon, Côte d'Ivoire was negative for all other SHERLOCK assays, as well as in all parasitological tests. In contrast, the TgsGP-positive sample from Guinea was positive in the multiplex pan-trypanosomatid SHERLOCK assay, as well as in the CATT and mAECT tests, but it was negative in the pan-*Trypanozoon* SHERLOCK assay. To further explore trypanosome diversity, species-specific SHERLOCK assays for AAT were applied to the samples. In total, 23.2 % [17.7, 28.7] (52/224) of the samples in Côte d'Ivoire and 7.5 % [3.8, 11.2] (15/200) in Guinea were positive for *T. congolense*. Additionally, a single sample from Côte d'Ivoire tested positive in the *T. suis*-specific SHERLOCK assay. Furthermore, no RNA from *T. vivax* or *T. theileri* was detected with the IFX SHERLOCK assay.




Figure 4.

Diversity of blood trypanosomatids among free-range pigs from Côte d'Ivoire assessed by the SHERLOCK4AAT toolbox.

(A) Map of the Côte d'Ivoire, the region where the samples were collected is highlighted in purple. (B) Results of the SHERLOCK4AAT screening of 224 pig samples collected in Côte d'Ivoire. The coloured dashed lines represent the detection thresholds set for each assay. Each colour represents a specific test: multiplex pan-trypanosomatid (green), pan-*Trypanozoon* (orange), *T. b. gambiense* (yellow), *T. congolense* (light green), *T. vivax* (purple), *T. theileri* (red), *T. simiae* (blue) and *T. suis* (black). (C) Table summarizing the number of positive samples as well as the percentage (%) positive infections for each test, calculated on the total number of samples analysed. The total number of samples analysed were 219 for the multiplex pan-trypanosomatid assay, 173 for the *T. vivax*-specific assay, and 224 for all other SHERLOCK assays. (D) Venn diagram representing the crossover between the positive samples analysed with the three tests (multiplex pan-trypanosomatid (green), pan-*Trypanozoon* (orange) and *T. congolense* (purple)) giving the highest prevalence. The percentage of the total is shown in brackets below the number of samples constituting each fraction.




Figure 5.

Diversity of blood trypanosomatids among farm pigs from Guinea assessed by the SHERLOCK4AAT toolbox.

(A) Map of Guinea showing the N'zérékoré prefecture where samples were collected in pink. (B) Results of the SHERLOCK4AAT screening of 200 pig samples collected in Guinea. The coloured dashed lines represent the detection thresholds set for each of the tests. Each colour represents a specific test: multiplex pan-trypanosomatid (green), pan-*Trypanozoon* (orange), *T. b. gambiense* (yellow), *T. congolense* (light green), *T. vivax* (purple), *T. theileri* (red), *T. simiae* (blue) and *T. suis* (black). (C) Table summarizing the number of positive samples as well as the percentage (%) positive infections for each test, calculated on the total number of samples analysed (n=200). (D) Venn diagram representing the crossover between the positive samples analysed with the three tests (multiplex pan- trypanosomatid (green), pan-*Trypanozoon* (orange) and *T. congolense* (purple)) giving the highest prevalence. The percentage of the total is shown in brackets below the number of samples constituting each fraction.

Interestingly, a substantial number of co-infections were observed. In total, 24/219 individuals (11.0 ± 4.1 %) in Côte d'Ivoire and 13/200 in Guinea (6.5 ± 3.4 %) tested positive in the multiplex pan-trypanosomatid, the pan-*Trypanozoon* and the *T. congolense*-specific assays. These triple positive results indicate co-infections involving both a *Trypanozoon* species (likely *T. b. brucei*) and *T. congolense* (Figure 4D and 5D). In addition, 9/219 samples (4.1 ± 2.6 %) from Côte d'Ivoire tested positive in the pan-*Trypanozoon* and the *T. congolense* assays, which also represented co-infections with *T. brucei* s.l. and *T. congolense*. Overall, 15.2 % [10.5, 19.9] of the samples from Côte d'Ivoire showed co-infections with a *Trypanozoon* species and *T. congolense*. Additionally, 15 samples from Côte d'Ivoire tested positive in both the multiplex pan-trypanosomatid assay and the *T. congolense*-specific assay or were positive only for *T. congolense*. In Guinea, two samples tested positive in both the *T. congolense*-specific and multiplex pan-trypanosomatid SHERLOCK assays, indicating *T. congolense* mono-infections (Figure 4D and 5D).

Furthermore, 56 samples (25.6 ± 5.8 %) in Côte d'Ivoire, and 38 samples (19.0 ± 5.4 %) in Guinea tested positive in both the multiplex pan-trypanosomatid and the pan-*Trypanozoon* SHERLOCK assays. In contrast, 17 samples from Côte d'Ivoire and 40 from Guinea tested positive in the pan-*Trypanozoon* assay but negative in the multiplex pan-trypanosomatid assay, likely due to the lower sensitivity of the latter. Lastly, 19 samples (8.7 ± 3.7 %) in Côte d'Ivoire and 19 samples (9.5 ± 4.1 %) in Guinea tested positive in the multiplex pan-trypanosomatid assay only (Figure 4D and 5D). The absence of positivity in the *T. congolense*, *T. simiae* and *T. suis*-specific assays may be due to their lower sensitivity, or to infections with other non-targeted trypanosome species.

Discussion

The SHERLOCK4AAT toolbox, a new panel of highly sensitive and specific high- throughput assays for detecting animal trypanosomes

Species identification is essential for assessing both the distribution of prominent parasites impacting veterinary health and spotting reservoirs for human-infective trypanosomes. In a context where symptoms are often mild and unspecific, especially in hosts like pigs, accurate species-specific detection methods are essential. Ideally, diagnostic assays should be able to analyse both fresh and stored (ambient temperature) samples to determine parasites circulating within a specific area.

In this study, conserved and species-specific targets have been used to adapt SHERLOCK for the detection of most members of the Trypanosomatidae family (Kinetoplastea class) (Supplementary Figure 3) of veterinary importance (pan- trypanosomatid), and species-specific assays to discriminate between the six most common animal trypanosomes species in the study regions: *Trypanozoon* (*T. b. brucei*, *T. evansi* and *T. equiperdum*), *T. congolense* (Savanah, Forest Kilifi and Dzanga- sangha), *T. vivax*, *T. theileri* (TthI, TthII and TthIII), *T. simiae* and *T. suis*. The design of both broad and species-specific assays was based primarily on sequences of the *18S rRNA* and *GAPDH* genes which, as well as being conserved across species (Supplementary Figure 1), are highly expressed and contain regions that allowed for species discrimination. However, for *T. vivax*, the single-copy *IFX* gene was selected for its high specificity (Romero-Ramirez et al., 2022). The first simple version of our pan-trypanosomatid assay employed a single crRNA guide and was previously used to evaluated blood samples from gHAT seropositive individuals with a specificity of 93% (95.4-98.6) (N'Djetchi et al., 2024). To increase the performances of this assay, we added a second crRNA guide into the reaction mix to target the same RPA amplicon during the SHERLOCK reaction, resulting in an increased test sensitivity (Figure 3 and Supplementary Figure 6). For *Trypanozoon* species, no sequences were identified to distinguish *T. b. brucei*, *T. evansi* (A and B) and *T. equiperdum* as these parasites cannot be easily differentiated using the *18S rRNA* gene. In

the future, other genes such as *RoTat1.2 VSG* or *ESAG6/7* could be explored to discriminate *T. evansi* from other *Trypanozoon* by SHERLOCK (Claes et al., 2004 [↗](#); Holland et al., 2001 [↗](#)). Overall, *in silico* and *in vitro* analyses enabled us to assess the analytical specificities of these new SHERLOCK assays, confirming that the targets selected were sufficiently specific to be used as diagnostic for the species and groups of species concerned.

Using parasite RNAs, the LoD of the SHERLOCK assays were estimated to range between 10 to 10³ parasites/mL for the pan-trypanosomatid assay, 10 parasites/mL for the pan-*Trypanozoon* and *T. theileri* assays, from 10 to 10³ parasites/mL for *T. congolense* and 10⁴-10⁵ parasites/mL for *T. vivax*. Most PCR-derived molecular techniques currently used for detecting animal trypanosomes have a detection limit of 1 to 10 parasites/mL using genus- or species-specific primers, 50 parasites/mL using pan-species ITS1 primers (Desquesnes et al., 2022a [↗](#)) or 5 parasites/mL using 18S rRNA-targeting primers (Deborggraeye et al., 2006 [↗](#)). The ROC analyses of the *T. brucei*, *T. congolense* and *T. vivax* SHERLOCK assays (Supplementary Figure 8C) also shown sensitivity and specificity comparable to those of the recently developed 7SL sRNA diagnostic test for Animal trypanosomosis (Contreras Garcia et al., 2022 [↗](#)). Therefore, in total, the analytical sensitivities obtained by the pan-trypanosomatid, pan-*Trypanozoon*, *T. theileri* and *T. congolense* SHERLOCK assays were comparable with those of other existing molecular tools. Yet, a significant difference in favour of using SHERLOCK4AAT is that it detects RNAs, probing for active infections. The *T. vivax* SHERLOCK assay, targeting the single-copy *IFX* gene (Autheman et al., 2021 [↗](#)), did not meet the sensitivity requirements for the molecular diagnosis of animal trypanosomes and would require the identification of another target. As no genetic material from parasites was available for developing *T. simiae* and *T. suis* SHERLOCK assays, LoDs were determined using synthetic RNA controls. Both assays were able to detect 10 to 100 fM of the synthetic controls, far from the detection capacity of SHERLOCK, which can detect synthetic targets at a concentration of 2 aM in optimal conditions (Gootenberg et al., 2017 [↗](#)).

In the current version of the SHERLOCK4AAT toolbox, each assay can be run in 2 h 30 min, in a two-step reaction, at 2.5 € (exclusive of initial sample processing) (Sima et al., 2022 [↗](#)). All tests are optimized for high throughput screening with a fluorescence readout; hence, they can be performed in standard lab conditions by a technician trained for basic molecular biology. SHERLOCK4AAT was not developed for direct case diagnosis in the field, but rather for eco-epidemiological surveillance at large scale. Considering the absence of trypanosome species-specific treatment for domestic animals, the future development of a RDT for AAT would only include the pan-trypanosomatid target or equivalent. This would however require further technical optimizations (TNA extraction, sensitivity, LFA, ...).

SHERLOCK4AAT profiling in Guinea and Côte d'Ivoire


Trypanosome species identification can be used to finely map the risk of AAT parasite transmission in these areas. After cattle, pigs are the main domestic hosts infected by animal trypanosomes, but they can also be reservoirs of *T. b. gambiense*. *T. b. gambiense* infections in pigs are frequently reported in Sub-Saharan Africa (Ebhodaghe et al., 2018 [↗](#); Okello et al., 2022a [↗](#)) and these domestic animals likely represent an underestimated reservoir of human-infective parasites (Büscher et al., 2018 [↗](#); Mehltitz and Molyneux, 2019 [↗](#)). This is all the more important than pigs are often raised in close proximity to humans, increasing the risk of animal to human trypanosome transmission, reinforcing our efforts to integrate the detection of both animal and human parasites in domestic pigs in a One Health perspective (Rotureau et al., 2022 [↗](#)).

In blood samples from Ivorian pigs, analyses with the SHERLOCK4AAT toolbox revealed 37.9 % positive samples for *Trypanozoon* RNAs and 23.2 % positive samples for *T. congolense* RNAs, with 15.2 % samples positive for both tests. In addition, no sample was positive for *T. vivax*, *T. theileri* or *T. simiae*, but one sample was positive in the *T. suis* assay and another positive for *T. b. gambiense*. These findings are consistent with the most recent known distribution of animal trypanosomes in free- ranging pigs raised in Côte d'Ivoire's historical gHAT foci. The use of conventional molecular

diagnostics on 97 free-range pigs resulted in an overall positivity rate of 57 % for *Trypanozoon* DNA (PCR-TBR) and 24 % for *T. congolense forest* DNA (PCR-TCF), with 14 % of pigs positive in both PCRs and none positive for *T. vivax* (PCR-TVW) (N'Djetchi et al., 2017 [↗](#); Traoré et al., 2021). The epidemiological status of AAT in Guinea is unclear, as no large-scale molecular studies have been published so far. The blood samples from farmed pigs analysed here were collected in the prefecture of N'zérékoré, a former endemic focus of gHAT. Results showed a positivity rate of 39.0 % for the detection of *Trypanozoon* RNAs, like that observed in Côte d'Ivoire, but a lower rate of positivity for *T. congolense* RNAs (7.5 %), with 6.5 % of samples positive for both tests. In addition, one sample tested positive for *T. b. gambiense*, but no *T. vivax*, *T. simiae*, *T. theileri* nor *T. suis* was detected. The lack of any samples positive for *T. vivax* or *T. theileri* in any study areas confirms that pigs are not frequent carriers of these species (Fetene et al., 2021 [↗](#)). However, the blood samples positive for *T. b. gambiense* in each study site provide further evidence of the ability of pigs to carry human trypanosomes and to act as potential reservoir. Similarly, the presence of *T. b. gambiense* genetic material in pig samples has already been suspected in Côte d'Ivoire (Traoré et al., 2021).

In both sites, a high prevalence of trypanosomatid parasites was observed using the multiplex pan-trypanosomatid and/or pan-*Trypanozoon* assays (42.0 % in Côte d'Ivoire and 48.5 % in Guinea). Having partially deconvolved the species present in these animals; there is still a small proportion (8.7 % in Côte d'Ivoire and 9.5 % in Guinea) of trypanosomatid parasites that remained uncharacterised by our tests on samples found only positive in the multiplex pan-trypanosomatid SHERLOCK assay. Firstly, these assays were designed by *in silico* determination of the most specific and conserved region to target the entire Trypanosomatidae family, and even Kinetoplastea class, or to discriminate between species, yet the limited number of sequences available for some species in the literature and in the online databases may under-represent the real genetic diversity of these parasites *in natura*. In line with this hypothesis, there may also exist uncharacterised trypanosome species circulating among these reservoirs, as described in small mammals in central and East Africa (Votypka et al., 2022), and that were only detected by the broad multiplex pan-trypanosomatid assay. Altogether, these results are consistent with those reported in the few available previous studies (N'Djetchi et al., 2017 [↗](#); Traoré et al., 2021) and confirm the effectiveness of the SHERLOCK4AAT toolbox in analysing the distribution of trypanosomes in hypo-endemic gHAT foci. During natural infections, trypanosome nucleic acids can be detected in the skin, adipose tissue and various organs even if the blood remains negative (Amisigo et al., 2024 [↗](#)). Trypanosome DNA also persists in blood and skin, even after drug treatment (Ekloh et al., 2023 [↗](#)). Hence, applying SHERLOCK detection on skin samples in the future would be useful for monitoring both blood and skin-dwelling parasites. The future development of multiplexed assays combined with adapted lateral flow tests would also be highly desirable for reaching field-applicable point-of-care molecular diagnostic versions of the tests useable in the field. The absence of point of care diagnostic test for AAT is currently a major hurdle for its surveillance and control (Desquesnes et al., 2022b [↗](#)).

T. b. gambiense is suspected to circulate among domestic animals raised in close contact to humans, such as pigs. Here, *T. b. gambiense* has been detected in one animal in each study site. Considering the resulting low prevalence of *T. b. gambiense* infections in these two populations of domestic pigs (0.45 ± 0.9 % in Côte d'Ivoire to 0.50 ± 1.0 % in Guinea) and the short life expectancy of domestic pigs reared for commercial purposes in these two rural areas (6 to 8 months), these animals do likely not represent a significant risk to the elimination of gHAT. This is apparently confirmed by the absence of new human cases as well as by the low abundance of tsetse flies in the two sites (article in preparation). However, because of their proximity to humans and their easy access for frequent sampling, pigs could be used as sentinels to monitor *T. b. gambiense* circulation, possibly with the SHERLOCK4AAT toolbox.



Supplementary Figure 1.

A: Representation of the proportions of identity between *18S rRNA* (A) and *GAPDH* (B) genes from Microsporidia, Ciliophora, Haemospororida, Diplomonadida, Symbiontida, Diplonemea, Euglenida and Kinetoplastea, focusing on several species within last family.

A

	RPA Forward Primer	target region crRNA 1	target region crRNA 3	RPA Reverse Primer
Microsporidia	CITTAATTGACTCAACGCGAGTAA	[...]ATATTTTATTATTCACGAGAAATGSA	[...]ATAGTGTGCATGGCCGTTTCAATGA	TGCT-GTAAAGT-TTTGATTAAATTC
Ciliophora	CITTAATTGACTCAACACTGGGAAA	[...]AGGGTAAGAA---GATTTAGGATTGACAGA	[...]GTGGTGTGCATGGCCGTTCTTAC-TGG	TGGA-GTGAGATGCTGGTTAAATTC
Haemosporidia	CITTAATTGACTCAACAGGCAAAA	[...]AGTTTAAGAC---AAAGTAGGATTGACAGA	[...]ATGGTAGTCATGSCCGCTTTTAACT-TGG	TGAATAGATTGCTCGGTTAAATTC
Diplomonadida	CTCAATCTGACTCAACGCGG-CAG	[...]AGGCTCGGAC---GC-CGAGG-CCACAGC	[...]GCGTGTGCATGSCCGCTCCCA-C-CG	TGGC-GCAGGCCCTCTGCTCATTC
Symbiontida	CITTAATTGACTCAACAGGCAAA	[...]AGATCAGAC---GCCGCTGGATTGACAGA	[...]ATGGTGTGCATGSCCGCTCCTGCT-TGG	TGGA-GTGATTGCTCGGTTGATTC
Diplonemea	CITTAATTGACTCAACAGGGAAT	[...]AGGTCAGAC---AATTAAGGATTGACAGA	[...]GTGGTGTGCATGSCCGCTCCTGCT-TGG	TGGA-GTGATTGCTCGGTTGATTC
Euglenida	CITTAATTGACTCAACGCGGGAAT	[...]AGGTCAGAC---GCACTGAGGATTGACAGA	[...]ACGTTGTGCATGSCCGCTCCTGAT-TGG	TGGA-GTGATTGCTCGGTTGATTC
Kinetoplastea	TTTAATTGACTCAACAGGGGAC	[...]AGATCGGAC---AGGGTGAGGATTGACAGA	[...]ATGGTGTGCATGSCCGCTTTTGT-CGG	TGGA-GTGATTGTTGGTTGATTC

B

	Forward RPA Primer	crRNA target region	Reverse RPA Primer
H, pdb 5VYC i	-----	[...]CCCCCGGCGCAGCTTC-----	
Pf1, XR_002966654.1	-----AAATATAT	[...]CATTTCTTAGGGAATGTGATTTT----	[...]TTCCTTCAGTACCTTA-----
Lm, GQ332361.1	CCGCGCCGCTTTTA---CAAATTAC	[...]TA-----TTGGCCTTTAC----	[...]TATCCTCAGCAGTTTCTG--TTTTTC
Tcz, AJ009147.1	TCCTGCCAATGAATATATTAAATTAC	[...]TT-----TTGGTCTTCGCTTTT	[...]TATCCTCAGCAGTTTATCTGA-CTTCTTC
Tvx, EU477537.1	GCGCTCCACCAACCA-----TCAC	[...]TTTGG-----CGGGCCCTCGC----	[...]TGTCTCAGCAGCTCC-----AACGGCC
Tcg, AJ009146.1	GTGCAGTCACACAA---ACAATTAC	[...]TGCTGCCGTACGTTGCGCCCTTATTTT	[...]TATCCTCAGCAGTTGTTTACATTTTC
Tth, AJ009163.1	CCTCGCCAATGGATA---TCAATTAC	[...]TT-----TTGGTCTTCGC----	[...]TATCCTCAGCAGTTTATCTGA-CTTCTTC
Tsm, AJ404608.1	CCACAGCCAATACAA---CAAATTAC	[...]TGCCGGGGGTCGCC-----	[...]TATCCTCAGCAGTTGTGA--CTCATTC
Tsu, MK954469.1	CGGTCCCAGTACTTA---ACAATTAC	[...]TTATATCCGCCIGGCGTGCTTCGTTGT	[...]TATCCTCAGCAC
Tbb, XR_002989632.1	GCCCAATTTATTTA---TCAATTAC	[...]TATCACCCCGGTTCCCTCTTTTGAGGT	[...]TATCCTCAGCAGTTTCTTA--CTTCTTC

Supplementary Figure 2.


(A) Alignments for 18S Pan-trypanosomatid SHERLOCK target region. The sequences used for the alignments are as follows: Microsporidia (*Nosema adalia*, KC412706.1), Ciliophora (*Vorticella sp.*, DQ487201.2), Haemosporidia (*Plasmodium falciparum*, XR_002966679.1), Diplomonadida (*Giargia intestinalis*, XR_005248679.1), Symbiontida (*Calkinsia aureus*, EU753419.1), Diplonemea (*Diplonema ambulator*, AY425009.1), Euglenida (*Euglena sanguinea*, JQ281806.1) and Kinetoplastea (*Trypanosoma (T) brucei brucei*, XR_002989632.1). (B) Alignments for 18S Pan-Trypanozoon SHERLOCK target region. The sequences used for the alignments are as follows: Human (H, pdb|5VYC|i), *Plasmodium falciparum* (Pf1, XR_002966679.1), *Leishmania major* (Lm, GQ332361.1), *T. cruzi* (Tcz, AJ009147.1), *T. vivax* (Tvx, EU477537.1), *T. congolense* (Tcg, AJ009146.1), *T. theileri* (Tth, AJ009163.1), *T. simiae* (Tsm, AJ404608.1), *T. suis* (Tsu, MK962702.1) and *T. brucei brucei* (Tbb, XR_002989632.1). Non-conserved bases between sequences are highlighted in bold.

BLAST exclusion	Range of amplicon percentage identity (arithmetic mean)	Number of sequences included	Percentage of sequences with conserved crRNA		Sequences with partially conserved crRNA	
			crRNA 1	crRNA 3	crRNA 1	crRNA 3
<i>Family</i> Trypanosomatidae	82.27 - 100% (98.4%)	1644	59.4 %	97.1 %	667	48
<i>Order</i> Trypanosomatida	82.27 - 100% (98.4%)	1652	59.6 %	97.1 %	667	48
<i>Subclass</i> Metakinetoplastia	81.88 – 100% (97.9%)	1931	57.6 %	94.8 %	818	100
<i>Class</i> Kinetoplastea	81.88 – 100% (97.3%)	2051	55.1 %	90.3 %	920	199
<i>Phylum</i> Euglenozoa	69.72 – 100% (91.7%)	3330	34.0 %	55.8 %	2199	1477
<i>Phylum Euglenozoa</i> (excluded Kinetoplastea)	69.72 – 98.55% (82.9%)	1287	0.6 %	0.7 %	1279	1278

Supplementary Figure 3.

Summary of BLAST analysis obtained against the 18S pan- trypanosomatid SHERLOCK amplicon and evaluation of the homology of the target region of each crRNA.

The percentage identity of the target amplicon of pan- trypanosomatid RPA was evaluated using different degrees of exclusion, to assess its percentage of identity within the different groups and especially in the Phylum Euglenozoa, excluding the target group Kinetoplastea. The number of sequences evaluated is shown, as well as the percentage of sequences where the target regions of the pan-trypanosomatid guides (crRNAs) are conserved.



Supplementary Figure 4.

Screening of different RPA pairs of primers and/or crRNAs guides for each SHERLOCK assay optimization.

In each evaluation a positive control (RNA from a target species, coloured bar) and a negative control (RNA from a non-target species, grey bar) were used. RPA pairs of primers are named A, B or C, while crRNAs were name from 1 to 10. The time point used is indicated. # indicates the combination of RPA primers and crRNA selected for the rest of the analysis. All inputs were used at a concentration of 5 ng/ μ L.

	Accession	Alignment against the crRNA	Identity (%)	Query coverage
<i>T. simiae</i>	KR024686.1	TCCCTGCTCCGGCGCGGGGCACTCGC	90.62	100%
	KP307021.1	TCCCTGCTCCGGCGCGGGGCACTCGC	90.62	100%
	AJ009162.1	TCCCTGCTCCGGCGCGGGGCACTCGC	90.62	100%
	AJ223569.1	TCCCTGCTCCGGCGCGGGGCACTCGC	90.62	100%
	U22320.1	TCCCTGCTCCGGCGCGGGGCACTCGC	90.62	100%
	KP307022.1	TCCCTGCTCCGGCGCGGGGCACTCGC	89.06	100%
	AJ404608.1	TCCCTACCTCGGCGCGGGGCACTCGC	86.72	100%
	U22318.1	TCCCTACCTCGGCGCGGGGCACTCGC	86.72	100%
<i>T. godfreyi</i>	AJ009155.1	TCCCTACCCGCGCGGGGCACTCGC	88.28	100%
<i>T. sapaensis</i>	AB242822.1	TCTCTGTTCCGGCTGCGGGGCACTCGT	88.28	100%
<i>Trypanosoma vivax</i>	EU477537.1	TCCCTGCTCCGGCGCGGGGCAACCCGC	87.50	100%
	KM391829.1	TCCCTGCTCCGGCGACGGGGCAACCCGC	84.38	100%
	KM391828.1	TCCCTGCTCCGGCGACGGGGCAACCCGC	84.38	100%
	KM391827.1	TCCCTGCTCCGGCGACGGGGCAACCCGC	84.38	100%
	KM391826.1	TCCCTGCTCCGGCGACGGGGCAACCCGC	84.38	100%
	KM391823.1	TCCCTGCTCCGGCGACGGGGCAACCCGC	84.38	100%
	KM391822.1	TCCCTGCTCCGGCGACGGGGCAACCCGC	84.38	100%
	HE573019.1	TCCCTGCTCCGGCGACGGGGCAACCCGC	84.38	100%
	U22316.1	TCCCTGCTCCGGCGACGGGGCAACCCGC	84.13	98%
	KM391825.1	TCCCTGCTCCGGCGACGGGTTCCACCGC	83.59	100%
	KM391824.1	TCCCTGCTCCGGCGACGGGTTCCACCGC	83.59	100%
	KM391821.1	TCCCTGCTCCGGCGACGGGTTCCACCGC	83.59	100%
	KM391820.1	TCCCTGCTCCGGCGACGGGTTCCACCGC	83.59	100%
	KM391818.1	TCCCTGCTCCGGCGACGGGTTCCACCGC	83.59	100%
	KM391816.1	TCCCTGCTCCGGCGACGGGTTCCACCGC	83.59	100%
	KM391819.1	TCCCTGCTCCGGCGACGGGTTCCACCGC	82.81	100%
<i>T. theileri</i>	KR024688.1	TCTCTGTTCCGGCGGTGGGGCAACTCAC	86.72	100%
	LC618031.1	TCTCTGTTCCGGCGGTGGGGCAACTCAC	86.72	100%
	AJ009163.1	TCTCTGTTCCGGCGGTGGGGCAACTCAC	86.72	100%
	AB007814.1	TCTCTGTTCCGGCGGTGGGGCAACTCAC	86.72	100%
	LC618030.1	TCTCTGTTCCGGCGGTGGGGCAACTCAC	85.94	79%
	JX178191.1	TCTCTGTTCCGGCGGTGGGGCAACTCAC	85.29	79%
	JX178190.1	TCTCTGTTCCGGCGGTGGGGCAACTCAC	84.31	79%
	MG255951.1	TCTCTGTTACGGCGGTGGGGCAACTCAC	85.42	75%
<i>Trypanosoma thomasi</i>	MG255958.1	TCTCTGTTCCGGCGGTGGGGCAACTCAC	84.38	75%
	KT728394.1	TCTCTGTTCCGGCGGTGGGGCAACTCAC	85.94	100%
	KT728393.1	TCTCTGTTCCGGCGGTGGGGCAACTCAC	85.94	100%
	KT728392.1	TCTCTGTTCCGGCGGTGGGGCAACTCAC	85.94	100%
	KT728391.1	TCTCTGTTCCGGCGGTGGGGCAACTCAC	85.94	100%
	KT728390.1	TCTCTGTTCCGGCGGTGGGGCAACTCAC	85.94	100%
	KT728389.1	TCTCTGTTCCGGCGGTGGGGCAACTCAC	85.94	100%
	KT728388.1	TCTCTGTTCCGGCGGTGGGGCAACTCAC	85.94	100%
	KT728387.1	TCTCTGTTCCGGCGGTGGGGCAACTCAC	85.94	100%
	KT728386.1	TCTCTGTTCCGGCGGTGGGGCAACTCAC	85.94	100%
	KT728385.1	TCTCTGTTCCGGCGGTGGGGCAACTCAC	85.94	100%
	KT728384.1	TCTCTGTTCCGGCGGTGGGGCAACTCAC	85.94	100%
	KT728383.1	TCTCTGTTCCGGCGGTGGGGCAACTCAC	85.94	100%
	KT728382.1	TCTCTGTTCCGGCGGTGGGGCAACTCAC	85.94	100%
	KT728381.1	TCTCTGTTCCGGCGGTGGGGCAACTCAC	85.94	100%
	KT728380.1	TCTCTGTTCCGGCGGTGGGGCAACTCAC	85.94	100%
	KT728379.1	TCTCTGTTCCGGCGGTGGGGCAACTCAC	85.94	100%
	KT728378.1	TCTCTGTTCCGGCGGTGGGGCAACTCAC	85.94	100%
	KT728377.1	TCTCTGTTCCGGCGGTGGGGCAACTCAC	85.94	100%
	KT728376.1	TCTCTGTTCCGGCGGTGGGGCAACTCAC	85.94	100%
	KT728375.1	TCTCTGTTCCGGCGGTGGGGCAACTCAC	85.94	100%
	KT728374.1	TCTCTGTTCCGGCGGTGGGGCAACTCAC	85.94	100%
	KT728373.1	TCTCTGTTCCGGCGGTGGGGCAACTCAC	85.94	100%
	OM509729.1	TCTCTGTTCCGGCGGTGGGGCAACTCAC	85.94	100%
	KT728396.1	TCTCTGTTCCGGCGATGGGGCAACTCAC	84.38	100%
	KT728395.1	TCTCTGTTCCGGCGATGGGGCAACTCAC	84.38	100%
crRNA 18STeg1		TCCCTGCTACGGCGCGGGGTGACTCGC		

Supplementary Figure 5.


Alignments of the 18S *T. congolense* SHERLOCK target region.

The sequences used for the alignments are from *T. simiae*, *T. godfreyi*, *T. sapaensis*, *T. vivax*, *T. theileri* and *T. thomasi*. Non-conserved bases between sequences are highlighted in grey. The percentage identity of each sequence was analysed against the RPA amplicon in the *T. congolense*-specific SHERLOCK assay.

Supplementary Figure 6.

Comparison of the limit of detection of the single and multiplex 18S pan-trypanosomatid SHERLOCK assays.


Single and multiplex 18S pan- trypanosomatid SHERLOCK assays on dilutions of *T. b. brucei* RNA and on RNA extracted from HEK human cells as negative control. N=9 for each dilution. Error bars represent standard deviations from the mean of the replicates.




Supplementary Figure 7.

Background cross-reactivity of the 18S pan-trypanosomatid (A) and 18S pan-*Trypanozoon* (B) SHERLOCK assays using genetic material extracted from pig blood as input.

Means are represented by single lines. Quantities of porcine and *T. b. brucei* genetic material extracts included in each trial are as follows: "-" none, "+" 1 ng/ μ L, "++" 2 ng/ μ L and "+++" 3 ng/ μ L.






Supplementary Figure 8.

Threshold determination for all new SHERLOCK4AAT assays.

(A) Compilation of positive and negative results obtained using multiplex pan- trypanosomatid and pan-*Trypanozoon* SHERLOCK tests and ROC curves obtained for each analysis. The red dotted line marks the selected threshold for each test. (B) Compilation of positive and negative results obtained using the species-specific SHERLOCK assays and ROC curve obtained for each analysis. The red dotted line marks the selected threshold for each test. (C) Summary of the analytical features of each SHERLOCK assay. Analytical sensitivity (95 % of CI), specificity (95 % of CI) and fold change cut-off.



Supplementary Figure 9.

Posterior sensitivity estimates of three SHERLOCK assays (multiplex pan-trypanosomatid, pan-*Trypanozoon* and *T. congolense*-specific SHERLOCK assays, red curve) to the three parasitological tests (buffy coat examination, mAECT and /or isolation in mice, orange curve) performed in parallel on the 224 pig blood samples from Côte d'Ivoire.

Estimates were obtained with the Monte Carlo method (Gibbs sampling) proceeding in an iterative chain.

Acknowledgements

The authors thank Annette MacLeod (University of Glasgow, Glasgow, UK) for providing RNA from *T. b. rhodesiense*, Nick Van Reet and Philippe Büscher (Institute of Tropical Medicine [ITM], Antwerp, Belgium) for providing RNA from *T. equiperdum*, *T. evansi* types A and B, Gerald Spaeth and Artur Scherf (Institut Pasteur, Paris, France) for providing RNA from *Leishmania major* and *Plasmodium falciparum* and John Kelly (The London School of Hygiene & Tropical Medicine, London, UK) for providing RNA from *T. cruzi*. We warmly thank all the colleagues at the University Jean Lorougnon Guédé (Daloa, Côte d'Ivoire) and at the Institut Pierre Richet (Bouaké, Côte d'Ivoire) as well as all the health workers in the districts of Sinfra and Bonon (Côte d'Ivoire) and N'zérékoré (Guinée) for their strong support in the field.

Additional information

Funding

This project was funded by the Agence Nationale pour la Recherche (ANR-21-CE17- 0022-01 SherPa), the Programme Investissement d'Avenir of the French Government through the two Laboratoires d'Excellence, ANR-10-LABX-62-IBEID and ANR-11- LABX-0024-PARAFRAP, and the Pasteur Network (Bourse Calmette-Yersin to AC).

Author contributions

RE, EPA, AC, LG and BR conceived and designed the experiments. RE, EPA, AC, SB, ADH, MND, MT, YL, BD, ADC, MK, VJ and JMB performed the experiments. RE, EPA, AC, PC, LG and BR analysed the data. MK, DK, MC, VJ, ST, JMB, BR and LG contributed reagents, materials and analysis tools. RE, EPA, AC, LG and BR wrote the manuscript. MND, MK, VJ, ST, and JMB reviewed the manuscript.

Funding

Agence Nationale de la Recherche (ANR-21-CE17-0022-01 SherPa)

Agence Nationale de la Recherche (ANR-10-LABX-62-IBEID)

Agence Nationale de la Recherche (ANR-11-LABX-0024-PARAFRAP)

Institut Pasteur (Bourse Calmette-Yersin)

Additional files

Sup Table 1. Accession numbers of organisms used to evaluate the presence of single nucleotide polymorphism (SNPs) in the different target regions. [↗](#)

Sup Table 2. Primers and crRNA guides used for the SHERLOCK4AAT toolbox. [↗](#)

Sup Table 3. RPA primers used to produce the in vitro transcribed targets (positive control templates). [↗](#)

References

1. Álvarez-Rodríguez A, Jin B-K, Radwanska M, Magez S (2022) **Recent progress in diagnosis and treatment of Human African Trypanosomiasis has made the elimination of this disease a realistic target by 2030** *Frontiers in medicine* **9**:1037094 <https://doi.org/10.3389/fmed.2022.1037094> | Google Scholar
2. Amisigo CM, Amegatcher G, Sunter JD, Gwira TM (2024) **Adipose and skin distribution of African trypanosomes in natural animal infections** *Parasites & vectors* **17**:215 <https://doi.org/10.1186/s13071-024-06277-7> | Google Scholar
3. Autheman D, Crosnier C, Clare S, Goulding DA, Brandt C, Harcourt K, Tolley C, Galaway F, Khushu M, Ong H, Romero-Ramirez A, Duffy CW, Jackson AP, Wright GJ (2021) **An invariant *Trypanosoma vivax* vaccine antigen induces protective immunity** *Nature* **595**:96–100 <https://doi.org/10.1038/s41586-021-03597-x> | Google Scholar
4. Barrett MP, Priotto G, Franco JR, Lejon V, Lindner AK (2024) **Elimination of human African trypanosomiasis: The long last mile** *PLoS neglected tropical diseases* **18**:e0012091 <https://doi.org/10.1371/journal.pntd.0012091> | Google Scholar
5. Boulangé A, Lejon V, Berthier D, Thévenon S, Gimonneau G, Desquesnes M, Abah S, Agboho P, Chilongo K, Gebre T, Fall AG, Kaba D, Magez S, Masiga D, Matovu E, Moukhtar A, Neves L, Olet PA, Pagabeleguem S, Shereni W, Sorli B, Taioe MO, Tejedor Junco MT, Yagi R, Solano P, Cecchi G (2022) **The COMBAT project: controlling and progressively minimizing the burden of vector-borne animal trypanosomosis in Africa** *Open research Europe* **2**:67 <https://doi.org/10.12688/openreseurope.14759.2> | Google Scholar
6. Brotánková A, Fialová M, Čepička I, Brzoňová J, Svobodová M (2022) **Trypanosomes of the *Trypanosoma theileri* Group: Phylogeny and New Potential Vectors** *Microorganisms* **10** <https://doi.org/10.3390/microorganisms10020294> | Google Scholar
7. Brown LD, Cai TT, DasGupta A (2001) **Interval Estimation for a Binomial Proportion** *Statistical Science* **16** <https://doi.org/10.1214/ss/1009213286> | Google Scholar
8. Budd LT. (2001) **Trypanosomosis, Tsetse and Africa** <https://assets.publishing.service.gov.uk/media/57a08d23e5274a31e0001686/ZC0135a.pdf> | Google Scholar
9. Büscher P, Bart J-M, Boelaert M, Bucheton B, Cecchi G, Chitnis N, Courtin D, Figueiredo LM, Franco J-R, Grébaut P, Hasker E, Ilboudo H, Jamonneau V, Koffi M, Lejon V, MacLeod A, Masumu J, Matovu E, Mattioli R, Noyes H, Picado A, Rock KS, Rotureau B, Simo G, Thévenon S, Trindade S, Truc P, van Reet N (2018) **Do Cryptic Reservoirs Threaten Gambiense-Sleeping Sickness Elimination?** *Trends in parasitology* **34**:197–207 <https://doi.org/10.1016/j.pt.2017.11.008> | Google Scholar
10. Claes F, Radwanska M, Urakawa T, Majiwa PA, Goddeeris B, Büscher P (2004) **Variable Surface Glycoprotein RoTat 1.2 PCR as a specific diagnostic tool for the detection of *Trypanosoma evansi* infections** *Kinetoplastid biology and disease* **3**:3 <https://doi.org/10.1186/1475-9292-3-3> | Google Scholar

11. Contreras Garcia M, Walshe E, Steketee PC, Paxton E, Lopez-Vidal J, Pearce MC, Matthews KR, Ezzahra-Akki F, Evans A, Fairlie-Clark K, Matthews JB, Grey F, Morrison LJ (2022) **Comparative Sensitivity and Specificity of the 7SL sRNA Diagnostic Test for Animal Trypanosomiasis** *Frontiers in Veterinary Science* **9** <https://doi.org/10.3389/fvets.2022.868912> | Google Scholar
12. Courtin F, Camara O, Camara M, Kagbadouno M, Bucheton B, Solano P, Jamonneau V (2019) **Maladie du sommeil dans le foyer historique de Guinée forestière : actualisation grâce à une méthode géographique.** *Parasite (Paris, France)* **26**:61 <https://doi.org/10.1051/parasite/2019061> | Google Scholar
13. Deborggraeve S, Claes F, Laurent T, Mertens P, Leclipteux T, Dujardin JC, Herdewijn P, Büscher P (2006) **Molecular dipstick test for diagnosis of sleeping sickness** *Journal of clinical microbiology* **44**:2884–2889 <https://doi.org/10.1128/JCM.02594-05> | Google Scholar
14. Desquesnes M, Gonzatti M, Sazmand A, Thévenon S, Bossard G, Boulangé A, Gimonneau G, Truc P, Herder S, Ravel S, Sereno D, Jamonneau V, Jittapalapong S, Jacquiet P, Solano P, Berthier D (2022a) **A review on the diagnosis of animal trypanosomoses** *Parasites & vectors* **15**:64 <https://doi.org/10.1186/s13071-022-05190-1> | Google Scholar
15. Desquesnes M, Sazmand A, Gonzatti M, Boulangé A, Bossard G, Thévenon S, Gimonneau G, Truc P, Herder S, Ravel S, Sereno D, Waleckx E, Jamonneau V, Jacquiet P, Jittapalapong S, Berthier D, Solano P, Hébert L (2022b) **Diagnosis of animal trypanosomoses: proper use of current tools and future prospects** *Parasites & vectors* **15**:235 <https://doi.org/10.1186/s13071-022-05352-1> | Google Scholar
16. Ebhodaghe F, Ohiolei JA, Isaac C (2018) **A systematic review and meta-analysis of small ruminant and porcine trypanosomiasis prevalence in sub-Saharan Africa (1986 to 2018)** *Acta tropica* **188**:118–131 <https://doi.org/10.1016/j.actatropica.2018.08.034> | Google Scholar
17. Ekloh W, Sunter JD, Gwira TM (2023) **African trypanosome infection patterns in cattle in a farm setting in Southern Ghana** *Acta tropica* **237**:106721 <https://doi.org/10.1016/j.actatropica.2022.106721> | Google Scholar
18. Fetene E, Leta S, Regassa F, Büscher P (2021) **Global distribution, host range and prevalence of *Trypanosoma vivax*: a systematic review and meta-analysis** *Parasites & vectors* **14**:80 <https://doi.org/10.1186/s13071-021-04584-x> | Google Scholar
19. Franco JR, Priotto G, Paone M, Cecchi G, Ebeja AK, Simarro PP, Sankara D, Metwally SBA, Argaw DD. (2024) **The elimination of human African trypanosomiasis: Monitoring progress towards the 2021-2030 WHO road map targets.** *PLoS neglected tropical diseases* **18**:e0012111 <https://doi.org/10.1371/journal.pntd.0012111> | Google Scholar
20. Giordani F, Morrison LJ, Rowan TG, de Koning HP, Barrett MP. (2016) **The animal trypanosomiasis and their chemotherapy: a review** *Parasitology* **143**:1862–1889 <https://doi.org/10.1017/S0031182016001268> | Google Scholar
21. Gootenberg JS, Abudayyeh OO, Lee JW, Essletzbichler P, Dy AJ, Joung J, Verdine V, Donghia N, Daringer NM, Freije CA, Myhrvold C, Bhattacharyya RP, Livny J, Regev A, Koonin EV, Hung DT, Sabeti PC, Collins JJ, Zhang F (2017) **Nucleic acid detection with CRISPR-Cas13a/C2c2** *Science* **356**:438–442 <https://doi.org/10.1126/science.aam9321> | Google Scholar
22. Holland WG, Claes F, My LN, Thanh NG, Tam PT, Verloo D, Büscher P, Goddeeris B, Vercruysse J (2001) **A comparative evaluation of parasitological tests and a PCR for *Trypanosoma***

evansi diagnosis in experimentally infected water buffaloes *Veterinary parasitology* **97**:23–33 [https://doi.org/10.1016/S0304-4017\(01\)00381-8](https://doi.org/10.1016/S0304-4017(01)00381-8) | Google Scholar

23. Joseph L, Gyorkos TW, Coupal L (1995) **Bayesian estimation of disease prevalence and the parameters of diagnostic tests in the absence of a gold standard** *American journal of epidemiology* **141**:263–272 <https://doi.org/10.1093/oxfordjournals.aje.a117428> | Google Scholar
24. Karshima SN, Lawal IA, Bata SI, Barde IJ, Adamu PV, Salihu A, Dross PN, Obalisa A (2016) **Animal reservoirs of *Trypanosoma brucei gambiense* around the old Gboko sleeping sickness focus in Nigeria** *Journal of parasitology and vector biology* | Google Scholar
25. Kellner MJ, Koob JG, Gootenberg JS, Abudayyeh OO, Zhang F (2019) **SHERLOCK: nucleic acid detection with CRISPR nucleases** *Nature protocols* **14**:2986–3012 <https://doi.org/10.1038/s41596-019-0210-2> | Google Scholar
26. Kristjansson PM, Swallow BM, Rowlands GJ, Kruska RL, de Leeuw PN. (1999) **Measuring the costs of African animal trypanosomosis, the potential benefits of control and returns to research** *Agricultural Systems* **59**:79–98 [https://doi.org/10.1016/S0308-521X\(98\)00086-9](https://doi.org/10.1016/S0308-521X(98)00086-9) | Google Scholar
27. Magang EMK, Kamga RMN, Telleria J, Tichit M, Crouzols A, Kaboré J, Hardy D, Bouaka CUT, Jamonneau V, Rotureau B, Kuete V, Bart J-M, Simo G (2023) **Prevalence of blood and skin trypanosomes in domestic and wild fauna from two sleeping sickness foci in Southern Cameroon** *PLoS neglected tropical diseases* **17**:e0011528 <https://doi.org/10.1371/journal.pntd.0011528> | Google Scholar
28. McGinnis S, Madden TL (2004) **BLAST: at the core of a powerful and diverse set of sequence analysis tools** *Nucleic acids research* **32**:W20–5 <https://doi.org/10.1093/nar/gkh435> | Google Scholar
29. Mehrlitz D, Molyneux DH (2019) **The elimination of *Trypanosoma brucei gambiense*? Challenges of reservoir hosts and transmission cycles: Expect the unexpected.** *Parasite epidemiology and control* **6**:e00113 <https://doi.org/10.1016/j.parepi.2019.e00113> | Google Scholar
30. Meyer A, Holt HR, Selby R, Guitian J (2016) **Past and Ongoing Tsetse and Animal Trypanosomiasis Control Operations in Five African Countries: A Systematic Review** *PLoS neglected tropical diseases* **10**:e0005247 <https://doi.org/10.1371/journal.pntd.0005247> | Google Scholar
31. Morrison LJ, Tait A, McCormack G, Sweeney L, Black A, Truc P, Likeufack ACL, Turner CM, MacLeod A (2008) ***Trypanosoma brucei gambiense* Type 1 populations from human patients are clonal and display geographical genetic differentiation** *Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases* **8**:847–854 <https://doi.org/10.1016/j.meegid.2008.08.005> | Google Scholar
32. N'Djetchi MK, Camara O, Koffi M, Camara M, Kaba D, Kaboré J, Tall A, Rotureau B, Glover L, Traoré MB, Koné M, Coulibaly B, Adingra GP, Soumah A, Gassama M, Camara AD, Compaoré CFA, Camara A, Boiro S, Anton EP, Bessell P, van Reet N, Bucheton B, Jamonneau V, Bart J-M, Solano P, Biéler S, Lejon V. (2024) **Specificity of serological screening tests and reference laboratory tests to diagnose gambiense human African trypanosomiasis: a prospective clinical performance study** *Infectious diseases of poverty* **13**:53 <https://doi.org/10.1186/s40249-024-01220-5> | Google Scholar

33. N'Djetchi MK, Ilboudo H, Koffi M, Kaboré J, Kaboré JW, Kaba D, Courtin F, Coulibaly B, Fauret P, Kouakou L, Ravel S, Deborggraeve S, Solano P, Meeûs T de, Bucheton B, Jamonneau V. (2017) **The study of trypanosome species circulating in domestic animals in two human African trypanosomiasis foci of Côte d'Ivoire identifies pigs and cattle as potential reservoirs of *Trypanosoma brucei gambiense*.** *PLoS neglected tropical diseases* **11**:e0005993 <https://doi.org/10.1371/journal.pntd.0005993> | Google Scholar
34. Okello I, Mafie E, Eastwood G, Nzalawahe J, Mboera LEG (2022a) **African Animal Trypanosomiasis: A Systematic Review on Prevalence, Risk Factors and Drug Resistance in Sub-Saharan Africa** *Journal of medical entomology* **59**:1099–1143 <https://doi.org/10.1093/jme/tjac018> | Google Scholar
35. Okello I, Mafie E, Eastwood G, Nzalawahe J, Mboera LEG, Onyoyo S (2022b) **Prevalence and Associated Risk Factors of African Animal Trypanosomiasis in Cattle in Lambwe, Kenya** *Journal of parasitology research* **2022**:5984376 <https://doi.org/10.1155/2022/5984376> | Google Scholar
36. Piepenburg O, Williams CH, Stemple DL, Armes NA (2006) **DNA detection using recombination proteins** *PLoS biology* **4**:e204 <https://doi.org/10.1371/journal.pbio.0040204> | Google Scholar
37. Radwanska M, Claes F, Magez S, Magnus E, Perez-Morga D, Pays E, Büscher P (2002) **Novel primer sequences for polymerase chain reaction-based detection of *Trypanosoma brucei gambiense*** *The American journal of tropical medicine and hygiene* **67**:289–295 <https://doi.org/10.4269/ajtmh.2002.67.289> | Google Scholar
38. Richards S, Morrison LJ, Torr SJ, Barrett MP, Manangwa O, Mramba F, Auty H (2021) **Pharma to farmer: field challenges of optimizing trypanocide use in African animal trypanosomiasis** *Trends in parasitology* **37**:831–843 <https://doi.org/10.1016/j.pt.2021.04.007> | Google Scholar
39. Rodrigues CMF, Garcia HA, Rodrigues AC, Pereira DL, Pereira CL, Viola LB, Neves L, Camargo EP, Gibson W, Teixeira MMG (2020) **Expanding our knowledge on African trypanosomes of the subgenus *Pycnomonas*: A novel *Trypanosoma suis*-like in tsetse flies, livestock and wild ruminants sympatric with *Trypanosoma suis* in Mozambique** *Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases* **78**:104143 <https://doi.org/10.1016/j.meegid.2019.104143> | Google Scholar
40. Romero-Ramirez A, Casas-Sánchez A, Autheman D, Duffy CW, Brandt C, Clare S, Harcourt K, André MR, Almeida Castilho Neto KJG de, Teixeira MMG, Machado RZ, Coombes J, Flynn RJ, Wright GJ, Jackson AP. (2022) **Vivaxin genes encode highly immunogenic, non-variant antigens on the *Trypanosoma vivax* cell-surface.** *PLoS neglected tropical diseases* **16**:e0010791 <https://doi.org/10.1371/journal.pntd.0010791> | Google Scholar
41. Rotureau B, Waleckx E, Jamonneau V, Solano P, Molia S, Debré P, Dellagi K, Morand S (2022) **Enhancing research integration to improve One Health actions: learning lessons from neglected tropical diseases experiences** *BMJ global health* **7** <https://doi.org/10.1136/bmjgh-2022-008881> | Google Scholar
42. Schisterman EF, Perkins NJ, Liu A, Bondell H (2005) **Optimal cut-point and its corresponding Youden Index to discriminate individuals using pooled blood samples** *Epidemiology* **16**:73–81 <https://doi.org/10.1097/01.ede.0000147512.81966.ba> | Google Scholar
43. Serem EK, Mburu DM, Abdullahi OA, Bargul JL (2024) **A scoping review on tsetse fly blood meal sources and its assay methods since 1956 to 2022** *Parasites & vectors* **17**:52 <https://doi.org/10.1186/s13071-024-06000-0> | Google Scholar

44. Sievers F, Higgins DG (2018) **Clustal Omega for making accurate alignments of many protein sequences** *Protein science : a publication of the Protein Society* **27**:135–145 <https://doi.org/10.1002/pro.3290> | Google Scholar
45. Sima N, Dujeancourt-Henry A, Perlaza BL, Ungeheuer M-N, Rotureau B, Glover L (2022) **SHERLOCK4HAT: A CRISPR-based tool kit for diagnosis of Human African Trypanosomiasis** *EBioMedicine* **85**:104308 <https://doi.org/10.1016/j.ebiom.2022.104308> | Google Scholar
46. Simo G, Rayaisse JB (2015) **Challenges facing the elimination of sleeping sickness in west and central Africa: sustainable control of animal trypanosomiasis as an indispensable approach to achieve the goal** *Parasites & vectors* **8**:640 <https://doi.org/10.1186/s13071-015-1254-y> | Google Scholar
47. Traoré BM, Koffi M, N'Djetchi MK, Kaba D, Kaboré J, Ilboudo H, Ahouty BA, Koné M, Coulibaly B, Konan T, Segard A, Kouakou L, Meeûs T de, Ravel S, Solano P, Bart J-M, Jamonneau V. (2021) **Free-ranging pigs identified as a multi-reservoir of *Trypanosoma brucei* and *Trypanosoma congolense* in the Vavoua area, a historical sleeping sickness focus of Côte d'Ivoire** *PLoS neglected tropical diseases* **15**:e0010036 <https://doi.org/10.1371/journal.pntd.0010036> | Google Scholar
48. Vourchakbé J, Tiofack ZAA, Kante TS, Mpoame M, Simo G (2020) **L'identification moléculaire de *Trypanosoma brucei* gambiense chez les porcs, les chiens et les petits ruminants naturellement infectés confirme les animaux domestiques comme réservoirs potentiels de la maladie du sommeil au Tchad.** *Parasite (Paris, France)* **27**:63 <https://doi.org/10.1051/parasite/2020061> | Google Scholar
49. Ye J, Coulouris G, Zaretskaya I, Cutcutache I, Rozen S, Madden TL (2012) **Primer-BLAST: a tool to design target-specific primers for polymerase chain reaction** *BMC bioinformatics* **13**:134 <https://doi.org/10.1186/1471-2105-13-134> | Google Scholar

Author information

Roger-Junior Eloiflin*

INTERTRYP, Université de Montpellier, Montpellier, France

*Equal contributions

Elena Pérez-Antón*

Trypanosome Molecular Biology Unit, Institut Pasteur, Université de Paris, Paris, France

*Equal contributions

Aïssata Camara*

Parasitology Unit, Institut Pasteur of Guinea, Conakry, Guinea

*Equal contributions

Annick Dujeancourt- Henry

Trypanosome Molecular Biology Unit, Institut Pasteur, Université de Paris, Paris, France

Salimatou Boiro

Parasitology Unit, Institut Pasteur of Guinea, Conakry, Guinea

Martial N'Djetchi

Unité de Formation et de Recherche Environnement, Université Jean Lorougnon Guédé, Daloa, Côte d'Ivoire

Mélika Taoré

Unité de Formation et de Recherche Environnement, Université Jean Lorougnon Guédé, Daloa, Côte d'Ivoire

Mathurin Koffi

Unité de Formation et de Recherche Environnement, Université Jean Lorougnon Guédé, Daloa, Côte d'Ivoire

Dramane Kaba

Unité de Recherche Trypanosomoses, Institut Pierre Richet, Bouaké, Côte d'Ivoire

Yann Le Pennec

Virology Unit, Institut Pasteur of Guinea, Conakry, Guinea

Bakary Doukouré

Virology Unit, Institut Pasteur of Guinea, Conakry, Guinea

Abdoulaye Dansy Camara

Programme National de Lutte contre la Trypanosomiase Humaine Africaine, Ministère de la Santé, Conakry, Guinea

Moïse Kagbadouno

Programme National de Lutte contre la Trypanosomiase Humaine Africaine, Ministère de la Santé, Conakry, Guinea

Pascal Campagne

Bioinformatics and biostatistics hub, Institut Pasteur, Paris, France

Mamadou Camara

Programme National de Lutte contre la Trypanosomiase Humaine Africaine, Ministère de la Santé, Conakry, Guinea

Vincent Jamonneau

INTERTRYP, Université de Montpellier, Montpellier, France

Sophie Thevenon

INTERTRYP, Université de Montpellier, Montpellier, France, Cirad, UMR INTERTRYP, Montpellier, France

Jean-Mathieu Bart

INTERTRYP, Université de Montpellier, Montpellier, France, Programme National de Lutte contre la Trypanosomiase Humaine Africaine, Ministère de la Santé, Conakry, Guinea

Lucy Glover

Trypanosome Molecular Biology Unit, Institut Pasteur, Université de Paris, Paris, France

For correspondence: lucy.glover@pasteur.fr

Brice Rotureau

Parasitology Unit, Institut Pasteur of Guinea, Conakry, Guinea, Trypanosome Transmission Group, Trypanosome Cell Biology Unit, Institut Pasteur, Université Paris Cité, Paris, France
ORCID iD: [0000-0003-0671-8999](https://orcid.org/0000-0003-0671-8999)

For correspondence: rotureau@pasteur.fr

Editors

Reviewing Editor

Clara Akpan

Michael Okpara University of Agriculture, Umudike, Nigeria

Senior Editor

Dominique Soldati-Favre

University of Geneva, Geneva, Switzerland

Reviewer #1 (Public review):

Summary:

The authors developed SHERLOCK4AAT, a CRISPR-Cas13a-based diagnostic toolbox for detecting multiple trypanosome species responsible for animal African trypanosomiasis. They created species-specific assays targeting six prevalent parasite species and validated the system using dried blood spots from domestic pigs in Guinea and Côte d'Ivoire. Field testing revealed high infection rates (62.7% of pigs infected) and, notably, the presence of human-infective parasites in domestic animals.

Major Strengths:

This study represents a valuable application of CRISPR-based detection technology to veterinary diagnostics, with strong potential for practical implementation. The authors conducted comprehensive validation, including statistical analyses to determine sensitivity and specificity, and demonstrated field utility through large-scale testing of 424 samples from two geographically distinct regions. The detection of human-infective parasites in pigs at both sites provides important One Health insights supporting integrated disease surveillance and has direct implications for public health policy and disease elimination programs. The methodology is robust, incorporating Bayesian statistical modeling and offering clear practical advantages such as dried blood spot compatibility and detection of active infections. The revised manuscript also addresses implementation considerations, including cost, training needs, and field logistics.

Major Weaknesses:

Some technical limitations constrain broader applicability. The assay for one key parasite species (*T. vivax*) shows suboptimal sensitivity, which may limit its utility in detecting this important pathogen. The current assay design does not distinguish between closely related species within the same subgenus—an important factor for certain epidemiological studies. Additionally, some assays relied on synthetic controls due to unavailable biological material, and the discussion on potential cross-reactivity with related kinetoplastid parasites is limited. Achievement of Aims: The authors clearly achieved their primary objectives of developing a sensitive, species-specific diagnostic system and demonstrating its applicability in real-world settings. The detection of human-infective trypanosomes in domestic pigs provides valuable epidemiological evidence in support of One Health strategies and targeted disease elimination efforts.

Impact and Utility:

This work responds to a well-documented need in veterinary diagnostics, where current methods often lack sensitivity or species discrimination. The system offers practical benefits for resource-limited settings through a short assay duration and compatibility with dried blood spot samples. While certain performance limitations may restrict broader adoption, the species identification capability represents a substantial advancement over existing approaches. The findings enhance our understanding of parasite diversity in livestock and their potential role as zoonotic reservoirs, with implications extending beyond veterinary medicine to public health surveillance and policy development.

Context:

This study makes a timely and relevant contribution to diagnostic epidemiology and One Health surveillance frameworks. The field-adapted use of advanced molecular detection technologies represents a significant step toward improved disease monitoring in regions where trypanosomiasis poses ongoing threats to animal health, agriculture, and human livelihoods. The cross-disciplinary implications for veterinary medicine, public health, and disease elimination programs underscore the broader significance of this work.

<https://doi.org/10.7554/eLife.106823.2.sa3>

Reviewer #2 (Public review):

Summary:

The manuscript is fundamental due to the significance of its findings. The strength of the evidence is compelling, and the manuscript is publishable since the corrections have been made.

Strengths:

Using a Novel SHERLOCK4AAT toolkit for diagnosis.

Identification of various sub-species of Trypanosomes.

Differentiating the animal sub-species from the human one.

Corrections Made:

Definite articles have been removed from the title.

The words of the title have been reduced to 15.

Typographical errors have been corrected.

Weaknesses:

None

<https://doi.org/10.7554/eLife.106823.2.sa2>

Reviewer #3 (Public review):

Summary:

The study adapts CRISPR-based detection toolkit (SHERLOCK assay) using conserved and species-specific targets for the detection of some members of the Trypanosomatidae family of veterinary importance and species-specific assays to differentiate between the six most common animal trypanosomes species responsible for AAT (SHERLOCK4AAT). The assays were able to discriminate between Trypanozoon (*T. b. brucei*, *T. evansi* and *T. equiperdum*), *T. congolense* (Savanah, Forest Kilifi and Dzanga sangha), *T. vivax*, *T. theileri*, *T. simiae* and *T. suis*. The design of both broad and species-specific assays was based primarily on sequences of the 18S rRNA, GAPDH (Glyceraldehyde-3-phosphate dehydrogenase) and invariant flagellum antigen (IFX) genes for species identification. Most importantly the authors showed varying limit of detection for the different SHERLOCK assays which is somewhat comparable to PCR-derived molecular techniques currently used for detecting animal trypanosomes even though some of these methodologies have used other primers that target genes such as ITS1 and 7SL sRNA.

The data presented in the study are particularly useful and of significant interest for diagnosis of AAT in affected areas.

Strengths:

The assays convincingly allow for the analysis and detection of most trypanosomes in AAT

Weaknesses:

Inability for the assay to distinguish *T. b. brucei*, *T. evansi* and *T. equiperdum* using the 18S rRNA gene as well as the IFX gene not achieving the sensitivity requirements for detection of *T. vivax*. Both *T. brucei brucei* and *T. vivax* are the most predominant infective species in animals (in addition to *T. congolense*), therefore a reliable assay should be able to convincingly detect these to allow for proper use of diagnostic assay.

<https://doi.org/10.7554/eLife.106823.2.sa1>

Author response:

The following is the authors' response to the original reviews.

Reviewer #1 (Public review):

Summary:

This study addresses a critical gap in veterinary diagnostics by developing a CRISPR-based diagnostic toolbox (SHERLOCK4AAT) for detecting animal African trypanosomosis. It describes the development and field deployment of SHERLOCK4AAT, a CRISPR-Cas13-based diagnostic toolbox for the eco-epidemiological surveillance of animal African trypanosomosis (AAT) in West Africa. The authors successfully created and validated species-specific assays for multiple trypanosomes, including T. congolense, T. vivax, T.

theileri, *T. simiae*, and *T. suis*, alongside pan-trypanosomatid and pan-Trypanozoon assays. The field validation in pigs from Guinea and Côte d'Ivoire revealed high trypanosome prevalence (62.7%), frequent co-infections, and importantly identified *T. b. gambiense* in one animal at each site, suggesting pigs may serve as potential reservoirs for this human-infective parasite.

A major strength of the study lies in its methodological innovation. By adapting SHERLOCK to target both conserved and species-discriminating sequences, the authors achieved high sensitivity and specificity in detecting *Trypanosoma* species. Their use of dried blood spots, validated thresholds through ROC analyses, and statistical robustness (e.g., Bayesian latent class modeling) provides a strong foundation for their conclusions.

The results are significant: over 60% of pigs tested positive for at least one trypanosome species, with co-infections observed frequently and *T. b. gambiense* detected in pigs at both sites. These findings have direct implications for the role of animal reservoirs in human disease transmission and underscore the value of pigs as sentinel hosts in gHAT elimination efforts.

The limitations are well acknowledged, particularly the suboptimal sensitivity of the *T. vivax* assay and the reliance on synthetic controls for *T. suis* and *T. simiae*. However, these limitations do not undermine the overall conclusions, and the paper provides a clear roadmap for further assay refinement and implementation.

This study offers a timely, impactful, and well-substantiated contribution to the field. The SHERLOCK4AAT toolbox holds promise for improving AAT diagnostics in resource-limited settings and advancing One Health surveillance frameworks.

Thank you

Strengths:

- (1) The adaptation of SHERLOCK technology for AAT represents a significant technical advancement, offering higher sensitivity than traditional parasitological methods and the ability to detect multiple species simultaneously.
- (2) Rigorously performed with validation using appropriate controls, ROC curve analyses, and Bayesian latent class modelling, establishing clear analytical sensitivity and specificity for most assays.
- (3) Testing 424 pig samples across two countries provides robust evidence of the tool's utility and reveals important epidemiological insights about trypanosome diversity and prevalence.
- (4) The identification of *T. b. gambiense* in pigs at both sites has significant implications for HAT elimination strategies and highlights the need for integrated One Health approaches.
- (5) The use of dried blood spots and RNA detection for active infections makes the approach practical for field surveillance in resource-limited settings.

Thank you

Weaknesses:

- (1) The manuscript would benefit from more detailed discussion of practical considerations such as cost, equipment requirements, and training needs for

implementing SHERLOCK in endemic areas and rural settings which would improve applicability.

This is now addressed in the revised discussion (end of the first section).

(2) Limited discussion of pig selection criteria: More justification for choosing pigs as sentinel animals and discussion of potential limitations of this approach would strengthen the manuscript.

Yes, this is now more clearly explained in the revised discussion (beginning of the first section).

(3) More details on why certain genes were targeted would strengthen the methods.

The first result section ‘Selection of targets for broad and species-specific SHERLOCK assays targeting AAT species (SHERLOCK4AAT)’ is already dedicated to extensively explaining target selection, hence we’re afraid we don’t know what could be added.

(4) Table formatting could be improved for readability.

(5) Some figures are complex and would benefit from additional explanations in the legends.

We have tried to improve these two aspects as much as possible in the revised manuscript.

Reviewer #2 (Public review):

Summary:

The manuscript is important due to the significance of the findings. The strength of evidence is convincing.

Thank you

Strengths:

(1) Using a Novel SHERLOCK4AAT toolkit for diagnosis.

(2) Identification of various sub-species of Trypanosomes.

(3) Differentiating the animal subspecies from the human one.

Thank you

Weaknesses:

(1) The title is too long, and the use of definite articles should be reduced in the title.

The title has been improved in the revised version.

(2) The route of blood sample collection in the animals should be well defined and explained.

This has been more clearly explained in the revised method section.

Reviewer #3 (Public review):

Summary:

*The study adapts CRISPR-based detection toolkit (SHERLOCK assay) using conserved and species-specific targets for the detection of some members of the Trypanosomatidae family of veterinary importance and species-specific assays to differentiate between the six most common animal trypanosome species responsible for AAT (SHERLOCK4AAT). The assays were able to discriminate between Trypanozoon (*T. b. brucei*, *T. evansi*, and *T. equiperdum*), *T. congolense* (Savannah, Forest Kilifi, and Dzanga sangha), *T. vivax*, *T. theileri*, *T. simiae*, and *T. suis*. The design of both broad and species-specific assays was based primarily on sequences of the 18S rRNA, GAPDH (Glyceraldehyde-3-phosphate dehydrogenase), and invariant flagellum antigen (IFX) genes for species identification. Most importantly, the authors showed varying limits of detection for the different SHERLOCK assays, which is somewhat comparable to PCR-derived molecular techniques currently used for detecting animal trypanosomes, even though some of these methodologies have used other primers that target genes such as ITS1 and 7SL sRNA. The data presented in the study are particularly useful and of significant interest for the diagnosis of AAT in affected areas.*

Thank you

Strengths:

The assays convincingly allow for the analysis and detection of most trypanosomes in AAT.

Thank you

Weaknesses:

*Inability for the assay to distinguish *T. b. brucei*, *T. evansi*, and *T. equiperdum* using the 18S rRNA gene, as well as the IFX gene, not achieving the sensitivity requirements for detection of *T. vivax*. Both *T. brucei brucei* and *T. vivax* are the most predominant infective species in animals (in addition to *T. congolense*), therefore, a reliable assay should be able to convincingly detect these to allow for proper use of the diagnostic assay.*

We agree with this point and aim to improve the toolbox for future studies.

Reviewer #1 (Recommendations for the authors):

(1) Provide additional details on the practicality of SHERLOCK deployment in the field, including training, costs, and infrastructure (potential challenges for field deployment, including suggestions for how to overcome these barriers).

This is now addressed in the revised discussion (end of the first section).

(2) Provide more detailed justification for choosing pigs as the main study species and discuss potential benefits and limitations of extending the approach to other livestock species.

Yes, this is now more clearly explained in the revised discussion (beginning of the first section).

(3) Add a comparison table comparing SHERLOCK4AAT performance metrics (sensitivity, specificity, LoD) with existing molecular diagnostic methods for AAT for ease of reference.

There are dozens of different serological, immunological and molecular approaches with highly variable levels of sensitivity and specificities already reviewed and compared in detail in two references from 2022 (Desquesnes et al. a and b), which we have cited, as well as in a newly added reference (EBHODAGHE F acta trop 2018). Hence, we decided to only refer to the most comparable studies in the present article.

(4) Review complex figures and improve legends for better readability and interpretation.

We have tried to improve this as much as possible in the revised manuscript.

Reviewer #2 (Recommendations for the authors):

(1) Reduce the number of words in the title from 28 to not more than 20.

The title has been improved in the revised version.

(2) Specify the particular route of collection of blood samples in the various animals.

Yes, this is now more clearly explained in the revised method section.

(3) Correct all typographical errors.

We have tried to improve this as much as possible in the revised manuscript.

Thanks. I wish you the best in your publication process.

Thank you

Reviewer #3 (Recommendations for the authors):

Minor comments

(1) The authors can expand the discussion to include other recent diagnostic assays for Animal trypanosomiasis, such as those that target other genes like tubulin.

Please see response to Review 1 point #3 above.

(2) The cost-effectiveness of the use of the assay can be discussed since the assay is expected to be used for work in some resource-deprived areas. For example, will it cost a researcher less to do a diagnosis with this assay relative to what is already available?

This is now addressed in the revised discussion (end of the first section).

(3) Is Cote d'Ivoire more endemic for AAT than Guinea? Will this account for the apparently consistent differences in the percentage of positive samples, or just because of the type of samples used from the two locations?

As the sampling method, sample preservation and sample analysis were the same for both groups - yes, it appears that pigs, at least for domesticated ones, in the study region of Cote d'Ivoire were more frequently infected than those in the study region of Guinea. It is however risky to extrapolate these observations to the AAT prevalence in the entire countries and/or to other mammals.

(4) Can the authors comment on how long one can store the samples for an effective and reliable assay?

The samples can be stored for several months at ambient temperature in a sealed bag with silica gel packages to reduce humidity. We have added this detail in the revised methods section.

(5) It is not clear whether the authors used conventional molecular diagnostics to compare the data obtained from this particular cohort of animals as reference is made to published data. It is not surprising that the SHERLOCK performed better than using parasitology-based methodology.

This is now addressed in the revised discussion.

(6) (Figure 4D-5D) should be 4D and 5D.

Thank you, this has been corrected.

<https://doi.org/10.7554/eLife.106823.2.sa0>